Review Article
Combining Nanotechnology and Gas Plasma as an Emerging Platform for Cancer Therapy: Mechanism and Therapeutic Implication

Milad Rasouli (1,2), Nadia Fallah (3), and Sander Bekeschus (4)

1Plasma Medicine Group, Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Jalale-Al-Ahmad Ave, 1411713137 Tehran, Iran
2Department of Physics and Institute for Plasma Research, Kharazmi University, 49 Dr. Mofatteh Ave, Tehran 15614, Iran
3Department of Cell and Molecular Biology, Faculty of Biological Sciences, Kharazmi University, 49 Dr. Mofatteh Ave, 31979-37551 Tehran, Iran
4ZIK Plasmatis, Leibniz Institute for Plasma Science and Technology (INP), Felix-Hausdorff-Str. 2, 17489 Greifswald, Germany

Correspondence should be addressed to Sander Bekeschus; sander.bekeschus@inp-greifswald.de

Received 29 July 2021; Revised 28 September 2021; Accepted 30 September 2021; Published 27 October 2021

Nanomedicine and plasma medicine are innovative and multidisciplinary research fields aiming to employ nanotechnology and gas plasma to improve health-related treatments. Especially cancer treatment has been in the focus of both approaches because clinical response rates with traditional methods that remain improvable for many types of tumor entities. Here, we discuss the recent progress of nanotechnology and gas plasma independently as well as in the concomitant modality of nanoplasma as multimodal platforms with unique capabilities for addressing various therapeutic issues in oncological research. The main features, delivery vehicles, and nexus between reactivity and therapeutic outcomes of nanoparticles and the processes, efficacy, and mechanisms of gas plasma are examined. Especially that the unique feature of gas plasma technology, the local and temporally controlled deposition of a plethora of reactive oxygen, and nitrogen species released simultaneously might be a suitable additive treatment to the use of systemic nanotechnology therapy approaches. Finally, we focus on the convergence of plasma and nanotechnology to provide a suitable strategy that may lead to the required therapeutic outcomes.

1. Introduction

Albeit progress continues, cancer remains a devastating disease in millions of patients worldwide. In 2020, over 19 million new cancer cases are projected to occur globally [1]. The standard treatments for cancer therapy include radiotherapy, chemotherapy, surgery, and immunotherapy. These therapeutic strategies yield inadequate therapeutic efficacy in some patients or have unfavorable safety profiles [2]. Another challenge of current treatment methods is the therapy resistance related to tumor cells’ intrinsic or acquired exit strategies to circumvent cytotoxic therapy effects [3]. For instance, tumors consistently comprise a mixture of drug-sensitive cells and stem cells, which leads to adaption and drug resistance [4]. Hence, efforts have been dedicated to exploiting multimodal, flexible, and multifunctional therapeutic modalities. In combination with main treatment strategies, nanomedicine helps overcome numerous oncotherapy obstacles and might reduce side effects for enhancing treatment tolerability of conventional treatment [5].

Nanotechnology refers to different designs of matter in nanoscale. This technology has emerged as a multidisciplinary scientific field, including physics, chemistry, engineering, and biology. In recent years, nanotechnology has gained much attention, especially in medicine, known as nanomedicine [6]. Nanoparticles (NPs) are utilized to treat, diagnose, image, and prevent disease spread in cancer. Different types of NPs with several properties, such as drug delivery, have been created to complement current treatments. Organic NPs (e.g., lipid-based and polymeric NPs) and inorganic...
NPs (e.g., silica NPs and quantum dots), or the combination of them, indicate an efficient oncotherapy by targeting solid tumors [7]. Improved drug solubility, stability in the bloodstream, target delivery to tumors, control released, and reduction in toxicity are the outstanding features that distinguish this strategy from other therapies. Besides, enhancement in permeability and retention is accompanied by a high accumulation of NPs in tumors compared to normal tissues [8].

Gas plasma, produced at body temperature by applying an electric field to one or a set of electrodes, represents a multimodal environment of physical and chemical factors [9]. This technology has introduced an exciting application to modern medicine, ranging from wound healing, decontamination and antiviral action, and surface modification to recently also cancer therapy [10, 11]. Plasma cancer therapy is one of the most investigated applications of this technology today by engaging multiple disciplines, including engineering, physics, biology, and medicine, to achieve a novel oncotherapeutic approach. With effective targeting of multiple cancer hallmarks, gas plasmas provide a cocktail of physicochemical agents having great potential for translational cancer medicine separately or in combinatorial use with conventional therapeutic modalities [12]. Gas plasma treatment is performed directly by bringing the target tissue in immediate contact with the plasma plume or indirectly by exposing liquids suitable for clinical practice [13]. At the level of preclinical studies, gas plasma treatment showed a selective antitumor action to some extent [14], improves combination chemotherapy [15], and inhibits metastatic spread [16]. It is understood that these actions result from the multi-ROS/RNS (reactive oxygen species/reactive nitrogen species) generation by gas plasmas [17]. Apart from this, gas plasma can be combined with conventional therapies [18] due to its adjustable and flexible properties [19]. This introduces gas plasma as a promising modality in cancer treatment, separately or in combination with conventional methods and new technologies.

In pursuit of an innovative oncotherapeutic strategy, the combination of nanoparticles and gas plasma with their main features is presented. Moreover, therapeutic outcomes, efficacy, and implication of each technology are being discussed. To advance cancer treatment modality development, the convergence of plasma and nanotechnology in oncology, especially the nexus between reactivity and therapeutic implications of these therapeutic modalities, is summarized. The future horizons with opportunities and challenges also are presented.

2. Nanotechnology as a Platform for Oncotherapy: Types of Material and Targeting Systems

Playing a significant role in the COVID-19 vaccine development [20], nanotechnology was once again introduced as a multifunctional platform in resolving healthcare-related challenges. Cancer nanomedicine, which utilized nanotechnology for combating cancer, received significant attention owing to the promising results. Here, we present the NPs used to treat cancer based on their main features. Further, with a particular focus on NPs delivery vehicles, the therapeutic implications are described in detail.

2.1. Main Features of Appropriate Nanoparticles for Cancer Treatment. By their tunable capacity for loading agents and the facilitation and accuracy in drug delivery [21], nanocarriers are proper candidates for experiments at the level of in vitro and in vivo research and clinical trials [22]. In general, the use of NPs, due to their properties in various cancers, might play an essential role in the effectiveness of treatment across biological barriers. Charge, hydrophobicity, and surface cloaking are the surface properties of NPs, and shape, size, elasticity, and porosity are their physical features. Altering these physicochemical properties is the changes the subsequent penetration and toxicity profiles of NPs [23].

The surface coating, shapes, size, and elasticity of NPs play crucial roles in their biodistribution and pharmacokinetics in clinical and preclinical experiments [24–26]. Besides, the rate of internalization is linked to the shape and size of NPs [27]. Spherical NPs are very common and gained trust during these years. However, nonspherical properties with their unique characteristics gained attention in recent years [28]. It is interesting to note that the shape of the NPs is more important for the attraction of macrophages and phagocytosis than their size [29]. Evidence suggests the deviating hydrodynamic manner of nonspheroidal NPs; so their circulation time in the blood is more extended than spheroid NPs [30]. The aggregation of NPs at tumors sites is regulated by their shape, too [31]. The size of NPs is directly related to their effectiveness and biological function in experiments. Further, the formation of nanocarriers and agents is affected by the NP size [32]. Regarding elasticity, soft NPs represent higher permanence in blood circulation compared to hard NPs. On the contrary, hard NPs demonstrate higher cellular uptake rates. Accordingly, soft and hard NPs, according to the type of organ, display varying distributions [33].

NPs can have a positive or negative surface charge based on different components employed during their production. The surface charge has a significant effect on the stability, encapsulation capacity, and biodistribution of NPs. For instance, a slightly negative charge causes a better accumulation of NPs in tumor tissue [34]. Surface hydrophobicity has an essential role in immune processing and phagocytosis through opsonization and quicker blood clearance. Nowadays, using PEGylation (covalent or noncovalent attachment of amalgamation of polyethylene-glycol for masking an agent to reduce antigenicity) and hiding surface charge and hydrophobicity enhances the durability of NPs in blood circulation [31, 35]. In addition to PEG, some other factors for NP coating include peptides and biological membranes for concealing NPs and giving them unique properties [36, 37]. Hence, the active targeting decrements toxic effects in nonmalignant cells and enhances cellular uptake of NP-based drugs in tumors.

NPs in drug delivery systems for oncotherapy can be coated with different organic or inorganic substances
containing, for instance, metals, polymers, carbon, lipids, and proteins. These NPs, based on their hydrophobic or hydrophilic properties, also can encapsulate different agents. For example, liposomes with their hydrophilic core are suitable for hydrophobic therapeutic compounds [38]. Concerning polymeric NPs, different types of polymers (synthetic or natural) with biocompatible and biodegradable properties are used for drug delivery. Emulsion polymerization, emulsion evaporation, emulsion diffusion, nanoprecipitation, salting-out, dialysis, and supercritical fluids are used for synthesizing polymeric NPs [39]. In recent decades, metal-based (inorganic) NPs made of gold, silver, superparamagnetic iron oxide, and quantum dots have been utilized for experimental therapy and especially tumor diagnosis [40, 41].

2.2. Nanoparticle Delivery Vehicles. NPs should have specific properties for the successful delivery of therapeutic agents to tumor tissue. First, NPs require a particular marker or antibody targeted against tumor cells to reduce side effects to nonmalignant tissues. All types of NPs, including micelles, liposomes, and polymeric NPs, can load antibodies on their surface to increase efficacy and improve clinical trials’ outcomes [42]. However, leakage of blood vessels and insufficient lymphatic drainage often result in drugs not reaching tumor cells sufficiently. Hence, targeted NP therapy is a suitable strategy to prevail these obstacles in tumor cells [8]. For instance, iron oxide NPs linked to anti-CD44 monoclonal antibodies are utilized for cancer cells with the high CD44 expression [43]. Polymeric and magnetic NPs coated with anti-HER2 antibodies are used for HER2-receptor-positive cancers, especially ovarian and breast cancer [44, 45]. Transferrin-coated liposomes are used for head and neck cancer [46] and glioblastoma [47].

At the same time, the immunological dimension of cancer therapy is increasingly being recognized, as evident by the advent and success of immunotherapies in the 21st century [48–50]. Therefore, NPs have been heavily investigated in the past decade for their effects of providing and stimulating antitumor immunity in several types of cancer. Notably, the versatility of NPs lies in their tunable composition and hence target penetration and delivery, as recently summarized for macrophage update [51]. As another example, NPs were shown to perform targeted delivery of miR-200c and a CXCR-4 antagonistic peptide that led to immunogenic cancer cell death (ICD), perpetuating antitumor immunity, decreasing immunosuppression, and abrogating the expression of immune checkpoints in the tumor microenvironment [52]. Primarily gold nanoparticles are envisioned to perform a dual role as immune regulators and drug delivery into the tumor tissue [53]. NPs were recently proposed as efficient vehicles for anticancer vaccines, owing to their unique properties in targeted delivery and tissue penetration [54]. Nevertheless, care must be taken that NPs do not overstimulate immunity, leading to multiple organ failures. Along those lines, other safety aspects need to be considered, including NP reactions with proteins in the blood, nonphysiological activation of platelets leading to coagulopathies, excessive cellular damage, and hemolysis [55]. By crossing biological barriers, some NPs can cause adverse effects on various organs kidney, liver, brain, and reproductive systems. For instance, aggregation of NPs in the reproductive system by toxicity inducing impair the cells related to reproductive function. Although the exact molecular mechanisms and signaling are not clear, apoptosis, stress oxidative, and inflammation are among the response of these organs to NP toxicity [56]. AgNPs are widely used for antimicrobial properties in medicine, but this kind of NP can cause alteration in neurobehavioral and organ development in offspring after long-term exposure. AgNPs passing the blood-brain barrier (BBB) and disrupting development in the fetal brain can induce oxidative stress causing sensitivity against infection [57].

The last factor for drug delivery in oncotherapy is controlled drug release, which some of the elements used for NP generation can regulate. The purpose of the controlled release of drugs from NPs is to preserve the drug coating during the NP journey in the bloodstream and increase its toxic effect once delivered to the purpose destination in the tumor microenvironment (TME) [58]. In general, it should be noted that the optimal concentrations are achieved after an appropriate dose is applied that allows maximum tumor toxicity while retaining acceptable levels of side effects [59]. Stimuli-responsive NPs for drug release are categorized into two groups responsive to either internal and external stimuli. For example, pH, temperature, electric field, magnetic fields, and glutathione levels are used as stimuli [60–62]. Moreover, polymeric NPs can release agents by a hydrolytic or enzymatic method called degradation-controlled release. In this strategy, bonds in the backbone of NPs are being destructed for triggering drug release [63]. The solvent-controlled release, which works based on osmosis or swelling, is another method for releasing drugs from NPs. The osmosis-controlled release is suitable for NPs with semipermeable membranes [64], while swelling-controlled release occurs in polymeric NPs with a glassy hydrophilic membrane [65]. In the latter, water can quickly enter the NPs present in, for instance, hydrogels, and there is a direct relation between the rate of water diffusion and drug release.

2.3. Therapeutic Outcomes of NPs in Oncology. One of the essential applications of NPs is their targeted delivery of agents for oncotherapy engineered according to the type of cancer and the therapeutic agents, as well as the unique properties of the nanoparticles (Table 1). Overall, the use of NPs for the treatment or diagnosis of cancer is not limited to preclinical experiments. There have been many successes in clinical trials in several cancer entities; albeit, approval for medical use still is awaited in many instances. Colorectal cancer, breast cancer, melanoma, and head and neck cancer are examples of using NPs in clinical trials [66]. Gold nanoparticles (AuNPs) induce toxicity in tumor cells, and their size is directly associated with the rate of permeance, leading to toxicity effect by increasing ROS/RNS levels and subsequently induce oxidative stress. AuNPs are also used for imaging and probing tumor tissues. This is facilitated by free electrons of gold atoms being exposed to light, which leads to collective oscillation, also known as localized surface plasmon resonance, and subsequent light.
Table 1: Selected studies using nanoparticles in oncotherapy.

| Tumor entity | Particle type | Main finding | Ref. |
|--------------|---------------|--------------|------|
| Preclinical studies | Polyurethane NPs, superparamagnetic iron oxide NPs coated with silica layers, mesoporous silica NPs, zinc oxide NPs, triphenylphosphonium-Pluronic F127 nanomicelles, cetuximab chitosan NPs, polymeric NPs, polyethyleneimine NPs coated with bovine serum albumin | Reduction in cancer cell survival, apoptosis induction (upregulating caspase-3, caspase-9, PARP, Bax), inhibition of lung tumor growth, pausing growth of cancerous cells, decrease in tumor size, induction of DNA leakage from nuclei by ROS/RNS, inhibition of metastasis, cell cycle arrest at G2/M phase, prevention of autophagy | [180–187] |
| Lung cancer | Porous silicon NPs, mesoporous magnetite NPs, PCE NPs, metal-organic frameworks, polymeric NPs (NVA-AA), porphyrin-based metal-organic framework carrier | Inhibition of metastasis; prevention of tumor growth; decrement of cell viability; suppression of cancer cell proliferation; reduction in tumor size; decrease in side effects; induction of apoptosis (downregulating Bcl-2 and upregulating caspase-3, UBA52, TIAL1, and PIP1C); suppression of cell motility and invasiveness; downregulating proteins involved in vesicular trafficking | [188–193] |
| Breast cancer | Selenium NPs, poly (lactic-co-glycolic) acid NPs with inorganic molybdenum octahedral cluster, Fe₃O₄ NPs, PEGNPs, chitosan copolymer-magnetic NPs, poly-ε-caprolactone NPs | Inhibition of cancer cell growth, cytotoxic effect on cancer cells, reduction of metastasis, decrease of cancer cell viability and cytotoxicity, increased the intracellular ROS/RNS, diminution of tumor volume | [194–199] |
| Ovarian cancer | Albumin NPs, chitosan NPs, perfluorooctylbromide-porphyrin grafted lipid NPs, biosynthesized silver NPs, superparamagnetic iron oxide coated with mesenchymal stem cell, silver and gold NPs, mesoporous silica NPs coated with folic acid chitosan-glycine complex, hydroxyapatite NPs coated with gum Arabic, PLGA NPs co-loaded with 5-fluorouracil and perfluorocarbon | Enhancement of cancer cells killing; improved antitumor efficacy; prevention of tumor growth and metastasis; decrement of tumor volume; enhancement of photodynamic effects against cancer cells (by increasing oxidative stress); induction of apoptosis (overexpression of caspase-3, caspase-9, bid, and Bax); reduction of immune system response and systemic side effects; fragmentation of DNA in cancer cells; increase in antimitotic effects | [200–207] |
| Colon cancer | Silver NPs, lanthanum oxide NPs, transferrin-conjugated porous silicon NPs, high-Z metal NPs, PEI surface-functionalized mesoporous silica NPs, PLGA NPs coated with polyvinyl alcohol and Poloxamer188, magnetic iron oxide NPs loaded trimethoxysilylpropyl-ethylenediamine triacetic acid, polymerized human serum albumin NPs, PEI-PEG-magnetic iron oxide NPs | Immense antitumor effect, increase in caspase activity, increase intrinsic and extrinsic apoptosis, diminution tumor cell viability, induce DNA damage and autophagic pathways, enhancing ROS/RNS, cancer cell migration, causing a rupture of the lysosomal membranes, inhibition of cancer cell proliferation, downregulation of crucial enzymes for DNA repair and replication in cancer cells, upregulation of tumor suppressors | [208–214] |
| Glioblastoma | Magnetic NPs, nitric oxide donor S-nitroso-N-acetylpenicillamine loaded liposomes, PLGA NPs, polyanhydride NPs, solid lipid NPs, porous coordination network-Fe (III) NPs | Tumor growth inhibition, efficient tumor retention, enhancement of cytotoxicity; decrease of cell proliferation, reduction in cancer metastasis and progression, overexpression of proapoptotic genes, induction of ROS/RNS, improvement of antitumor treatment efficacy | [215–220] |
| Pancreatic cancer | Superparamagnetic y-Fe₂O₃ iron oxide with SiO₂-CaO shell NPs, zinc oxide NPs; Fe ions-releasing mesoporous NPs, NPs with magnetic inner core and polymeric outer shell, alendronate-poly(amideamine) NPs, metal-organic framework NPs | Increase of cytotoxicity in cancer cells, suppression of cancer cell growth, induction of apoptosis, exhibition of anticancer action, inhibition of the formation of osteoclasts, prevention of metastasis, induction of the polarization of tumor-resident macrophages to M1 phenotype | [221–226] |
| Bone cancer | Selenium NPs, PLGA-PEG NPs, superparamagnetic iron oxide NPs, human serum albumin-coated NPs of (2) Ga, lipid-polymer hybrid NPs, manganese oxide–mesoporous silica, hexagonal boron nitride NPs | High anticancer activity, induction of tumor cell death via necrosis, increase of cytotoxicity, tumor regression, cell death induction, disruption of lysosomal structure in cancer cells, attenuation of lysosomal protease activity, modulator of autophagy | [227–232] |
emission. Moreover, especially smaller AuNPs transmute light to heat and, as a result, are suitable for photothermal therapy [67, 68]. Due to their simple synthesis, suitable pharmacokinetics, and low toxicity profile, gold nanoparticles have drawn significant attention in the field of cancer therapy in recent years [69, 70].

Quantum dots are known as semiconductor NPs, and their characteristics originate from their ability to scatter fluorescent light from the visible to the infrared spectrum after excitation [71]. Quantum dots can help image small tumors in their initial stage that are otherwise difficult to diagnose [72]. Moreover, to better recognize tumor cells, they can be conjugated to different types of antibodies on their surface, which helps increase their utilization in clinical trials [73]. Polymeric-based NPs generally are made from naturally degradable materials such as polysaccharides, chitosan, hyaluronic acid, alginate, dextran, protein-based polymers, collagen, gelatin, and albumin, which do not cause toxic effects in the human body but can exert antitumor effects based on their cargo [39]. As an example of polymeric NPs, hyaluronic acid can affect tumor cell proliferation and angiogenesis, while albumin NPs can penetrate the blood-brain barrier. Chitosan NPs, by their unique features, have an essential role in tumor growth inhibition and apoptosis induction [74].

Lipid-based NPs consist of natural hydrocarbons or are being derived from plants and animal material. They can also be composed of synthetic phospholipids, cholesterol for membrane bilayer, and sphingolipids. For increasing therapy efficacy, lipid-based NPs can be conjugate with polymeric residues such as PEG and PEI (polyethyleneimine). Their form is usually spherical, and by active targeting, they can enter the cell through the endosome and release the drug inside the cytosol [75, 76]. Lipid-based NPs can inhibit migration and invasion of tumor cells and improve the internalization of anticancer drugs loaded on lipid-based NPs compared to free drugs [77]. Mesoporous silica NPs are another widely used type of NPs, having a high capacity for encapsulating therapeutic agents and showing adjustable drug release. They are also utilized for optical imaging, ultrasound, and magnetic resonance imaging, and positron emission tomography [78]. Furthermore, the alterable pore size of mesoporous silica NPs makes them a good option for proteins transfer [79]. Besides, they can easily be decorated with...
different small molecules including folate, transferrin, VEGF, IGF, EGF, C-type lectin, mannoside, asialoglycoprotein, and monoclonal antibodies targeting, for instance, HER2, CD44, TLR9, and integrins as a marker to improve the detection of cancer cells [80]. Ultimately, this can lead to decreased tumor volumes owing to enhanced cellular uptake of the NPs.

The mainstay of future clinical cancer treatment is combination therapy between novel technologies and conventional strategies. Nanomedicine and gas plasma as documented oncotherapeutic modalities have great potential to potentially improve cancer treatment due to the multifunctional capacity of NPs and the multimodal nature of gas plasmas.

3. Plasma Oncology: Processes, Efficacy, and Mechanisms of Action and Challenges

Medical gas plasma technology, also known as cold physical plasma, is a partially ionized gas generated at atmospheric pressure and operated at body temperature. It is distinguished for generating a complex physicochemical plasma, is a partially ionized gas generated at atmospheric pressure. Medical gas plasma technology, also known as cold physical plasma oncology, has great potential to potentially improve cancer treatment due to the multifunctional capacity of NPs and the multimodal nature of gas plasmas.

Mechanisms of Action and Challenges

At the same time, UV and microwave emissions of NPs and the multimodal nature of gas plasmas. Among them, the first true (cold) medical gas plasma devices intended for medically accredited use in dermatology centers in Europe [95]. Notwithstanding, it is understood that despite different geometries and ROS/RNS profiles, gas plasma treatment overall produces similar effects, being stimulating at low doses, treatment times, or energy input, and toxic at higher doses, treatment times, or energy input as predicted by the concept of hormesis [82].

Direct plasma treatment and gas plasma-treated solution (PTS) are two very different plasma treatment procedures. Direct treatment transfers all physical and chemical agents concomitantly on target, especially the short-lived ROS/RNS unique to the gas plasma technology. When treating a liquid, some of the species can be retained in such liquid and stored for later therapeutic use. This concept is called plasma-oxidized liquids (POL) that can be used for clinical application if using solutions certified as medical products such as sodium chloride [13]. Alternative names for the concept are plasma-treated liquids (PTL), plasma-treated solution or saline (PTS), plasma-activated medium (PAM), and plasma-activated liquid (PAL), among others [96]. POL recently has received significant attention in widespread areas, especially where direct plasma treatment has faced challenges. Several animal models have shown the versatility of POL [97–99]. Current challenges include its large bulk liquid generation, storage, sterility, and the lack of animal studies showing a benefit of such liquids over concentration-matched hydrogen peroxide solutions.

3.2. Cocktail of Physical and Chemical Factors in Gas Plasmas. ROS/RNS are produced in several stages based on plasma interaction with air, liquid, and matter and appear to play a vital role in the plasma therapy process [94]. The most important aspect of plasma differentiation, along with the diversity of physical and chemical factors and their combination, is their controlled and adjustable transfer to the biological target. Thus, depending on the input factors (e.g., discharge voltage, external electric field, target capacitance above ground, gas flow rate, and quenching gas shielding), a specific concentration of ROS/RNS is generated, which is not achievable in any other conventional cancer treatment methods [17], including photodynamic therapy. At the same time, UV and microwave emissions, positive ions, and electrons as main output parameters are highly related to the input parameters; albeit, their individual contribution to anticancer effects has not been studied so far, primarily because of the lack of ability to separate such factors from the ubiquitous ROS/RNS being generated simultaneously. For more detail regarding the nexus between the inputs and output parameters, see [100].

Apart from identifying the chemistry being critical for biomedical gas plasma effects, the short half-life of generated
ROS/RNS [101] and the low penetration depth of species in cells and tissues [102] remain a practical challenge in some applications. For example, the half-life of hydrogen peroxide, nitrite, nitrate, and ozone is on minutes to hours scale, depending on the temperature, whereas for other species such as atomic oxygen, hydroxyl, and nitric oxide, it varies between nanoseconds to seconds [103–105]. Although it has been reported that gas plasma triggers tissues effects in cm ranges, it has to be kept in mind, however, that the penetration depth of the most reactive species is about a few micrometers only, which is not enough to penetrate the tissue and seems appropriate for superficial skin lesions treatment. Notwithstanding, the signaling function of these gas plasma-derived ROS/RNS seems to transport information deep into tissues, as demonstrated using hyperspectral imaging of murine gas plasma-treated skin and wounds [106–108]. Hence, the current model is that superficial layers are being oxidized by the gas plasma-generated ROS/RNS, subsequently leading to PTMs and oXPTMs (oxidative post-translational modifications) on biomolecules, ultimately being sensed by cells and translated into differential signaling responses [109]. OxPTMs are increasingly recognized as signaling agents in, for example, neurodegenerative and cardiovascular disease [110–112]. Oxidative distress occurs at supraphysiological ROS/RNS concentrations, and cell and tissue damage may be induced directly [113]. The biological responses can then affect neighboring cells via paracrine routes via soluble factors or communication via junctional proteins to deeper layers of the tissue [107, 114]. The other physiochemical parameters of gas plasma are thought to play a minor role. UV radiation is present but relatively weak [115]. Electric fields are moderate with dielectric barrier discharges [116] and helium plasma jets [117] and weak for the clinically relevant argon plasma jet kINPen, but the fields on their own cannot recapitulate the plasma effect.

3.3. Anticancer Effects and Mechanisms of Gas Plasma Therapy. Even though significant progress has been achieved in recent years, the exact dose definition and optimization of plasma devices remain a debate due to the variety of plasma devices, different therapeutic procedures, and input factors affecting the composition of the produced plasma. Primarily, the concentration of produced ROS/RNS is considered the plasma dose, and based on that, the effect of gas plasma on cancer cells is classified in the majority of cases as programmed cell death as evident in vitro [17], in vivo [93], in ovo [118], and ex vivo in human patient samples [119]. At low doses, gas plasma exposure causes autophagy, senescence, and cell cycle arrest. Concomitant modality of gas plasma and silymarin nanoemulsion (SN) resulted in autophagy activation in human melanoma cells (G-361) [120]. Besides, it was reported that the cell viability of AMEC and HEC50 cells, relevant to endometrial cancer, was decreased through POL treatment, and this was related to the induction of autophagic cell death [121]. Furthermore, short gas plasma exposure led to a senescence phenotype in the adipose-derived stromal cells (ASC) and dermal fibroblasts [122]. Senescence induction was also found in melanoma cells following gas plasma exposure [123]. This was found to be related to calcium influx [124]. Simultaneously, several studies showed that gas plasma treatment induces cell cycle arrest. Lung adenocarcinoma (A549 cells), epidermal papilloma (308 cells), glioblastoma (U87MG cells), epidermal carcinoma (PAM212 cells), and wild-type keratinocytes are among the reported cell line that gas plasma able to induce cell cycle arrest in them, especially at G2/M and G1/S and checkpoints [15, 125, 126].

Regardless of the various affected signaling, apoptosis is the most documented type of cell death that has been evaluated following gas plasma treatment. It can be claimed that the induction of apoptosis has been shown in the majority of cancer types that have been studied yet by gas plasma and POL. For example, we recently indicated that POL with high selectivity induces intrinsic apoptosis in chemotherapy-resistant ovarian cancer cells accompanied by high expression of p53, Bax, and caspase-3 [127]. Overall, in moderate concentrations of ROS/RNS, apoptosis is induced by gas plasma exposure.

Interestingly, gas plasma can induce ICD, a type of cell death eliciting an immune response that is highly important in progress on plasma oncology [128]. To overcome the penetrating depth challenges of gas plasmas-generated ROS/RNS into tumors, inducing ICD by gas plasma is the milestone of this multidisciplinary technology to introduce gas plasma as an emerging approach to complement traditional and novel oncotherapeutic modalities such as immunotherapies. This was previously shown in a vaccination model in mice [129] and in a model of elevating protein immunogenicity in a melanoma model [86]. The immune-stimulating effects of gas plasma were very recently shown to be dramatic, showing direct evidence of abscopal effects in a syngenic breast cancer tumor model in vivo [93]. Such effects are observed at high treatment energies or long exposure times, while low energy and short treatment times were also documented to be beneficial for tissue regeneration, including proangiogenic, and wound healing effects [130].

Further, nonprogrammed cell death might occur under a high dose of ROS/RNS so that both normal and cancer cells are affected and might cause undesirable hallmark effects and tissue damage. Therefore, the concentration of ROS/RNS should be adjusted for acquiring a unique environment for oncotherapy through gas plasma. Besides the aforementioned therapeutic efficacies, selectivity towards cancer and normal cells has been described in some reports [131–133]. The selectivity mechanism has been ascribed to the chemistry of gas plasma and the fundamental difference between cancer and healthy cells. Briefly, the high ROS/RNS baseline, more abundant aquaporins in cell membranes, and the lower cholesterol content in cancer cells versus healthy counterparts form the basis of selectivity [134–137].

It is important to note that several end-stage head and neck cancer patients have benefited from clinical gas plasma treatment using the medically accredited atmospheric pressure argon plasma jet kINPen MED [138]. Tissue analysis revealed induction of apoptosis but not severe side effects [139, 140]. Based on the results and responding vs. nonresponding patients, it was hypothesized that the immune
system might have contributed to the therapeutic effects observed [141].

4. Future Horizons: Convergence of Plasma and Nanotechnology in Oncology

Although the combination of nanotechnology and gas plasma is still in preclinical settings, the results show a new strategy that in the future might be able to advance the efficacy of conventional therapies. Here, we emphasize the complementary role of plasma and nanotechnology technologies in improving each other’s performance and highlight their main features that led to promising results. In addition, the nexus between reactivity and their therapeutic implications and potential challenges for translating into clinical uses are presented as the basis for a future innovative trend in cancer treatment.

4.1. How Nanotechnology and Gas Plasma Complement Each Other. Considering the multifunctional and practical properties of nanotechnology platforms and gas plasmas in addressing various cancer hallmarks, the combination or concomitant modality of these technologies arises an emerging strategy towards personalized medicine for cancer patients [142]. Albeit advances in nanomedicine are more than plasma oncotherapy, gas plasmas with promising outcomes led to the emergence of multimodal, safe, and controllable therapy for cancer treatment. While the complexity of tumor morphology on the one hand and the toxicity of some NPs on the other are the biggest challenges of nanomedicine in cancer therapy, the low penetration of gas plasma-produced ROS/RNS and the complexity of controlling and determining gas plasmas’ dose are the essential troubles in plasma cancer therapy [143, 144].

The proposed synergy of gas plasma and NPs is such that in addition to improving each other’s strengths, they also cover each other’s limitations (Figure 1). NPs have great potential to combine locally with gas plasma-generated ROS/RNS [145]. Moreover, the combinational use of gas plasma with NPs might reduce the minimum NPs concentration required, decreasing NPs toxicity as a novel strategy. Gas plasma improves the delivery of NPs and increases ROS/RNS in the target tissue. Such mechanisms have been previously shown in gas plasma-treated murine and human skin [107, 146–148]. Moreover, one of the most promising applications of these two technologies is the combination with chemotherapy drugs [149–151]. The potential combinatory routes are numerous and include, for instance, extrinsic and intrinsic apoptosis, enhanced drug transporter activity, DNA damage, oxidative stress, mitochondrial membrane collapse, growth factor deprivation, and enhanced immune cell activity. Interestingly, in dermal applications, plasma appears to facilitate the penetration of NPs into the upper layers of the skin, and one hypothesis is that this is based on the plasma-generated electric fields [152]. In particular, transdermal delivery is an exciting field for combining plasma and nanotechnology, where the plasma-derived electric field is the most crucial factor for the efficient transfer of biological materials such as proteins, NPs, dextrans, and liposomes [153–155].

Due to the peroxynitrite production, gas plasma reduces the pH of tissue fluid or tissue in a rapid and reversible process and creates the acidic conditions required for the delivery of NPs [156, 157]. Another mechanism affecting the delivery NPs is the localized variation of temperature as adjuvant treatment in preclinical studies [158]. We have recently observed that the combination of hyperthermia with gas plasma leads to encouraging results for melanoma cancer treatment (unpublished observation). Therefore, the combination of hyperthermia, gas plasma, and nanomedicine seems to lead to an innovative combination therapy by increasing membrane fluidity, reducing tissue pH, and targeted transfer. Furthermore, the electric fields generated by the plasma possibly improve the magnetic NPs’ performance for cancer therapy.

4.2. Relationship between Reactivity and Therapeutic Implications of These Therapeutic Modalities. Regardless of the types of cancer, NPs, and plasma devices, the combination of NPs and gas plasmas led to encouraging results. Regarding the mechanisms and effectiveness, current research is directed to the production of ROS/RNS and increase of NPs uptake. The currently available studies on combining NPs and gas plasma treatment in vitro and in vivo are summarized in Table 2.

Glioblastoma is the most studied tumor with a combination of gas plasmas and AuNPs, and numerous studies have emphasized the efficacy of concomitant treatments of these technologies compared to each of them. Increased cancer cell death, activation of tumor suppressors, inhibition of tumor growth, reduction of migration and invasion in cancer cells, increased induction of apoptosis, increased E-cadherin in treated tissues, and decreased tumor volume have been presented as a collection of the main findings. The action mechanisms were related to the production of ROS/RNS and enhancement of the uptake of NPs [154, 159–162].

Similar results for melanoma were obtained when gas plasmas and NPs were used together. The increase of ROS/RNS resulting from the combination of different configurations of gas plasma with FAK antibody conjugated-AuNPs, silica, silver, iron oxide, cerium oxide, titanium oxide, iron-doped titanium oxide NPs, and Anti-EGFR-AuNPs leads to a significant increase of early apoptosis and secondary necrosis, reduction in G2/M levels, increase in the sub-G1 fraction, FAS externalization, caspase-8 activation, increase of selective cancer cell death, inhibition the viability of cancer cells, and reduction of growth pattern [163–167].

In addition to the antiproliferative effects and induction of cytotoxic effects, decreased metastatic gene expression and increased cellular internalization of NPs have previously been revealed, where fluorouracil-loaded PLGA NPs and gas plasmas concomitantly are utilized as novel solutions for breast cancer oncotherapy [149]. Further, combined use of iron NPs and plasma jet exposure reduces cell proliferation and induces apoptosis and DNA fragmentation in breast cancer [168].
Iron oxide-based magnetic NPs and plasma jet treatment have previously been used to cause cell cycle arrest at the G0/G1 phase, apoptosis induction, condensation of nuclei, restraining tumor growth, intensive necrosis, and reduction of tumor size in lung cancer considering the high-level generation of ROS/RNS [169].

4.3. Challenges to Achieving Clinical Success and Future Needs. To avoid undesirable effects and target incurable tumors effectively, the mainstay strategy is combination therapies, which aims for cotreatments and integrating novel modalities with traditional methods. To this end, nanomedicine is combined with gas plasma as a multimodal and encouraging platform, as seen in the promising outcomes of preclinical studies. Based on these studies and the properties of gas plasma and NPs, the synergy of these two technologies can become an anticancer treatment strategy in the future. In particular, it is hoped that the synthesis of NPs with gas plasma or processing and subsequent plasma treatment will improve NPs in terms of preventing the degradation of conjugated drugs, delivery of optimum concentration and fluxes in desirable time, and improving the pharmacokinetics of the drug, which is consequently aimed to lead to enhanced cancer cell death and immunogenicity. Importantly, multifunctional and multimodal natures of NPs and gas plasma create a unique environment for cancer treatment.

Despite the increasing number of studies on cancer nanomedicine, there is a striking imbalance between preclinical and clinical applications, and the number of approved NPs, which are using for the clinical settings, is relatively limited [170]. Regarding plasma medicine, several devices have so far received accreditation as medical device class IIa in Europe [130]. However, plasma application in cancer patients has been mostly performed within exploratory studies [138, 171–175], and a guideline-based indication of plasma devices in cancer treatment is not given as of now. State-of-the-art NP synthesis methods, which can address some challenges of traditional bulk techniques, have not been considered in most clinical trials. Besides, a gap between preclinical and clinical studies indicates the need for additional clinical trials, especially given the acceptable safety profiles of some of the approaches (Table 1). As for the challenges facing plasma, since most research groups use self-made devices, the most critical issue is the lack of a specific framework for standardizing plasma devices. In addition, the multiplicity of factors involved in plasma processing and treatment causes obstacles to the definition of plasma dose. Therefore, more studies with the same treatment process and device are needed in addition to efforts to standardize and optimize these two technologies. An exciting option to combine both technologies would be to treat molecules or substances, including NPs, with gas plasma while the treated target has been modified to store the chemical energy of the short-lived plasma-derived ROS/RNS. At the delivery site in the TME, the highly reactive ROS/RNS modification can then perform the oxidative action to bring the gas plasma to the point of care via a detour.
| Particle and gas plasma type                                      | Main finding                                                                 | Tumor entity | Ref.          |
|------------------------------------------------------------------|-------------------------------------------------------------------------------|--------------|---------------|
| AuNPs and helium-based plasma jet                                 | (i) Enhancement of the intracellular formation of superoxide and hydroxyl radical  
(ii) Decrease in intracellular glutathione  
(iii) Increase early apoptosis and secondary necrosis  
(iv) Caused a significant increase in the sub-G1 fraction  
(v) Reduction in G2/M levels  
(vi) FAS externalization and caspase-8 activation          | Melanoma     | [163]         |
| AuNPs and plasma jet                                             | (i) Increase of cell death  
(ii) Production of ROS/RNS  
(iii) decrease of cancer cells viability                    | Glioblastoma | [154]         |
| Anti-NEU AuNPs and surface type air plasma                       | (i) Reduction of proliferation rate  
(ii) Increase of selective cancer cell death                | Melanoma     | [164]         |
| PEG-coated AuNPs and surface DBD air plasma                      | (i) Decrease cancer cells viability  
(ii) Inhibiting tumor cell proliferation  
(iii) ROS/RNS-mediated apoptosis  
(iv) Activation of tumor suppressors  
(v) Inhibition of tumor growth  
(vi) Reduction of migration and invasion in cancer cells  
(vii) Decrease of tumor volume  
(viii) Increase of E-cadherin in treated tissues            | Glioblastoma | [159]         |
| AuNPs and DBD plasma                                            | (i) Augmentation of anti-cancer cytotoxicity  
(ii) Increasing AuNP endocytosis and trafficking to lysosomes in cancer cells  
(iii) Enhancement of AuNP uptake                              | Glioblastoma | [160]         |
| AuNPs and plasma jet                                             | (i) Decrease of cell viability  
(ii) Improvement of NPs uptake rate into cells  
(iii) Increment of ROS/RNS intensity in the cancer cells     | Glioblastoma | [161]         |
| FAK antibody conjugated-AuNPs and DBD plasma                    | (i) Inhibition of the viability of cancer cells  
(ii) Induction of apoptosis  
(iii) Decrease of cell cycle phase in G1  
(iv) Increase of the number of apoptotic cells                | Melanoma     | [165]         |
| Fluourouracil loaded PLGA NPs and plasma jet                     | (i) Induction of cytotoxic effects  
(ii) Decrease of metastatic gene expression  
(iii) Enhancement of anti-cancer effects  
(iv) Exhibited anti-proliferative effects  
(v) Increase of cellular internalization of NPs              | Breast cancer | [149]         |
| Iron NPs and plasma jet                                          | (i) Reduction in cell proliferation  
(ii) Induction apoptotic process  
(iii) Showed DNA fragmentation  
(iv) Increment of cancer cell death                           | Breast cancer | [168]         |
| Epidermal growth factor conjugated AuNPs and DBD plasma         | (i) Increase in cytotoxicity  
(ii) Enhancement of the apoptotic response                    | Lung cancer  | [249]         |
| Silica, silver, iron oxide, cerium oxide, titanium oxide, and iron-doped titanium oxide NPs, and plasma jet | (i) Reduction of growth pattern  
(ii) Increased cytotoxic effects  
(iii) ROS/RNS generation                                      | Melanoma     | [166]         |
| AuNPs and plasma jet                                             | (i) Increase of apoptotic cell death  
(ii) Induction of nuclear condensation and DNA fragmentation | Colorectal cancer | [250]         |
Finally, there are future challenges for NP drug discovery and development in oncology. First, standardized procedures in production for research and commercial applications will help accelerate results translated from bench to bedside [176]. Second, organo-typic 3D cultures much more resemble the clinical pathology of cancer tissues than 2D cultures while being faster and more ethical animal models, potentially allowing for screening many different types of functionalized NPs, which will eventually allow propelling the field to clinically relevant approaches at higher speeds [177, 178]. Third, novel functionalization techniques such as genetically engineered cell membranes may aid the targeted delivery of NPs’ cargo [179]. Last, preclinical research would vastly benefit from adhering to standardized protocols on studying NPs and assessing their drug delivery and distribution, as proposed by the National Cancer Institute (NCI) [179].

5. Conclusions
Nanomedicine and gas plasmas have been considered appropriate options for future oncotherapy due to the

| Particle and gas plasma type                  | Main finding                                                                 | Tumor entity   | Ref.  |
|-----------------------------------------------|------------------------------------------------------------------------------|---------------|-------|
| Iron oxide-based magnetic NPs and plasma jet  | (i) Decrease of cell viability                                               | Lung cancer   | [169] |
|                                              | (ii) Indication of high levels of ROS/RNS                                    |               |       |
|                                              | (iii) G0/G1 Phase cell cycle arrest and condensation of nuclei                |               |       |
|                                              | (iv) Inhibitory effect on cell migration and invasion                        |               |       |
|                                              | (v) Indicating intensive necrosis and apoptosis                              |               |       |
|                                              | (vi) Inhibition of cancer cells proliferation                                |               |       |
|                                              | (vii) Restraining tumor growth and reduction of tumor size                   |               |       |
| PLGA-magnetic iron oxide NPs and plasma jet  | (i) Inhibition of cancer cells proliferation                                 | Lung cancer   | [142] |
|                                              | (ii) Enhancement of cytotoxicity                                              |               |       |
|                                              | (iii) Induction of necrosis and apoptosis                                     |               |       |
|                                              | (iv) Increase of intracellular ROS/RNS levels                                 |               |       |
| Production of AuNPs by gas plasma            | (i) Reduction of invasive cancer cell proliferation                          | Breast cancer | [251] |
|                                              | (ii) Induction of cancer cell apoptosis                                       |               |       |
|                                              | (iii) Impairment of cell migration                                            |               |       |
| Platinum NPs and plasma jet                  | (i) Decrease in the viability of cancer cells                                | Lymphoma      | [252] |
|                                              | (ii) Enhancement the percentage of apoptosis cells                            |               |       |
|                                              | (iii) Increment in the percentage of DNA fragmentation                       |               |       |
|                                              | (iv) Decrease of cells in the G1 cell cycle phases                           |               |       |
|                                              | (v) Induction of ROS/RNS production                                           |               |       |
|                                              | (vi) Augment of intracellular Ca^{2+} levels                                  |               |       |
| AuNPs and gas plasma                         | (i) Gas plasma-stimulated AuNP uptake                                        | Glioblastoma  | [162] |
|                                              | (ii) Constant production of ROS/RNS (especially H_{2}O_{2}, NO_{2}^{-}, and NO_{3}^{-}) |               |       |
|                                              | (iii) Gas plasma-induced lipid peroxidation                                   |               |       |
|                                              | (iv) Increase of AuNPs uptake through endocytosis                            |               |       |
| Anti-EGFR-AuNPs and air plasma               | (i) Increment of death rate and proliferation                               | Melanoma and oral cancer       | [167] |
|                                              | (ii) Increase necrosis                                                       |               |       |
| PEG-AuNPs and plasma jet                     | (i) Production of singlet oxygen                                             |                | [253] |
|                                              | (ii) Hot electrons cause gold–PEG bond                                       |               |       |
| Curcumin loaded on triphosphate chitosan NPs | (i) Decrease of cell viability                                               | Breast cancer | [254] |
| by plasma jet                                | (ii) Induction of sub-G1; arrest of G2/M                                      |               |       |
|                                              | (iii) Upregulation of TP53 mRNA expression as a tumor suppressor             |               |       |
|                                              | (iv) Increase in the percentage of apoptotic cells                           |               |       |
promising preliminary results. To improve nanomedicine’s efficacy, combination with novel therapeutic modalities such as gas plasmas should be taken into account. Cocktail of ROS/RNS and electric fields of gas plasma and the NPs’ ability to precisely targeting and penetrating tissues creates a putative oncotherapeutic platform for cancer treatment by enhancing selectivity and targeting chemotherapy resistance. Even though synergistic efficacy of NPs and gas plasmas are reported, more studies are essential to elucidate underlying mechanisms and impact on aggressive cancers.

**Abbreviations**

NPs: Nanoparticles  
ROS: Reactive oxygen species  
RNS: Reactive nitrogen species  
ICD: Immunogenic cell death  
TME: Tumor microenvironment  
AuNPs: Gold nanoparticles  
PTMs: Posttranslational modifications  
PTS: Plasma-treated saline  
TLR: Toll-like receptor  
PEG: Polyethylene glycol  
ASC: Adipose-derived stromal cells  
PEI: Polyethyleneimine.

**Conflicts of Interest**

The authors declare no conflict of interest.

**Authors’ Contributions**

Milad Rasouli and Nadia Fallah contributed equally to this paper as first authors.

**Acknowledgments**

SB has acquired and received funding from the German Federal Ministry of Education and Research (BMBF, grant number 03Z22DN11).

**References**

[1] H. Sung, J. Ferlay, R. L. Siegel et al., “Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA: a Cancer Journal for Clinicians, vol. 71, pp. 209–249, 2021.

[2] K. Fitzner, F. Oteng-Mensah, P. Donley, and E. A. F. Heckinger, “Safety of cancer therapies: at what cost?,” Population Health Management, vol. 20, pp. 318–328, 2017.

[3] Y. Sun, “Tumor microenvironment and cancer therapy resistance,” Cancer Letters, vol. 380, pp. 205–215, 2016.

[4] H. C. Zheng, “The molecular mechanisms of chemoresistance in cancers,” Oncotarget, vol. 8, 2017.

[5] G. Housman, S. Byler, S. Heerboth et al., “Drug resistance in cancer: an overview,” Cancers (Basel), vol. 6, no. 3, pp. 1769–1792, 2014.

[6] S. E. McNeil, “Nanotechnology for the biologist,” Journal of Leukocyte Biology, vol. 78, pp. 585–594, 2005.

[7] L. Salvioni, M. A. Rizzuto, J. A. Bertolini, L. Pandolfi, M. Colombo, and D. Prosperi, “Thirty years of cancer nanomedicine: success, frustration, and hope,” Cancers (Basel), vol. 11, 2019.

[8] D. Peer, J. M. Karp, S. Hong, O. C. Farokhzad, R. Margalit, and R. Langer, “Nanocarriers as an emerging platform for cancer therapy,” Nature Nanotechnology, vol. 2, pp. 751–760, 2007.

[9] T. von Woedtke, S. Reuter, K. Masur, and K. D. Weltmann, “Plasmas for medicine,” Physics Reports, vol. 530, pp. 291–320, 2013.

[10] D. B. Graves, “Low temperature plasma biomedicine: a tutorial review,” Physics of Plasmas, vol. 21, 2014.

[11] S. Bekeschus, A. Kramer, E. Suffredini, T. von Woedtke, and V. Colombo, “Gas plasma technology—an asset to healthcare during viral pandemics such as the covid-19 crisis?,” IEEE Trans Radiat Plasma Med Sci, vol. 4, pp. 391–399, 2020.

[12] X. Dai, K. Bazaka, E. W. Thompson, and K. K. Ostrikov, “Cold atmospheric plasma: a promising controller of cancer cell states,” Cancers (Basel), vol. 12, 2020.

[13] E. Freund and S. Bekeschus, “Gas plasma-oxidized liquids for cancer treatment: pre-clinical relevance, immuno-oncology, and clinical obstacles,” IEEE Transactions on Radiation and Plasma Medical Sciences, pp. 1–1, 2020.

[14] S. Bekeschus, G. Liebelt, J. Menz et al., “Tumor cell metabolism correlates with resistance to gas plasma treatment: the evaluation of three dogmas,” Free Radical Biology & Medicine, vol. 167, pp. 12–28, 2021.

[15] J. Koritzer, V. Boxhammer, A. Schafer et al., “Restoration of sensitivity in chemo-resistant glioma cells by cold atmospheric plasma,” PLoS One, vol. 8, article e64498, 2013.

[16] S. Hasse, T. Meder, E. Freund, T. von Woedtke, and S. Bekeschus, “Plasma treatment limits human melanoma spheroid growth and metastasis independent of the ambient gas composition,” Cancers (Basel), vol. 12, p. 2570, 2020.

[17] A. Privat-Maldonado, A. Schmidt, A. Lin et al., “Ros from physical plasmas: redox chemistry for biomedical therapy,” Oxidative Medicine and Cellular Longevity, vol. 2019, Article ID 9062098, 2019.

[18] G. Pasqual-Melo, R. K. Gandhirajan, I. Stoffels, and S. Bekeschus, “Targeting malignant melanoma with physical plasmas,” Clinical Plasma Medicine, vol. 10, pp. 1–8, 2018.

[19] S. Bekeschus, A. Schmidt, F. Niessner, T. Gerling, K. D. Weltmann, and K. Wende, “Basic research in plasma medicine - a throughput approach from liquids to cells,” Journal of Visualized Experiments, vol. e56331, 2017.

[20] A. Khurana, P. Allawadhi, I. Khurana et al., “Role of nanotechnology behind the success of mrna vaccines for covid-19?,” Nano Today, vol. 38, article 101142, 2021.

[21] S. Wilhelm, A. J. Tavares, Q. Dai et al., “Analysis of nanoparticle delivery to tumours,” Nature Reviews Materials, vol. 1, 2016.

[22] V. Sanna and M. Sechi, “Therapeutic potential of targeted nanoparticles and perspective on nanotherapies,” ACS Medicinal Chemistry Letters, vol. 11, pp. 1069–1073, 2020.

[23] Z. Zhao, A. Ukidve, V. Krishnan, and S. Mitragotri, “Effect of physicochemical and surface properties on in vivo fate of drug nanocarriers,” Advanced Drug Delivery Reviews, vol. 143, pp. 3–21, 2019.

[24] J. A. Champion, Y. K. Katare, and S. Mitragotri, “Particle shape: a new design parameter for micro- and nanoscale drug
delivery carriers,” *Journal of Controlled Release*, vol. 121, pp. 3–9, 2007.

[25] P. Aggarwal, J. B. Hall, C. B. McLeland, M. A. Dobrovolskaia, and S. E. McNeil, “Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy,” *Advanced Drug Delivery Reviews*, vol. 61, pp. 428–437, 2009.

[26] S. Mitragotri and J. Lahann, “Physical approaches to biomaterial design,” *Nature Materials*, vol. 8, pp. 15–23, 2009.

[27] S. Muro, C. Garnacho, J. A. Champion et al., “Control of endothelial targeting and intracellular delivery of therapeutic enzymes by modulating the size and shape of icam-1-targeted carriers,” *Molecular Therapy*, vol. 16, pp. 1450–1458, 2008.

[28] Y. Y. Khine and M. H. Stenzel, “Surface modified cellulose nanomaterials: a source of non-spherical nanoparticles for drug delivery,” *Materials Horizons*, vol. 7, pp. 1727–1758, 2020.

[29] G. Sharma, D. T. Valenta, Y. Altman et al., “Polymer particle shape independently influences binding and internalization by macrophages,” *Journal of Controlled Release*, vol. 147, pp. 408–412, 2010.

[30] Y. Geng, P. Dalhaimer, S. Cai et al., “Shape effects of filaments versus spherical particles in flow and drug delivery,” *Nature Nanotechnology*, vol. 2, pp. 249–255, 2007.

[31] X. Duan and Y. Li, “Physicochemical characteristics of nanoparticles affect circulation, biodistribution, cellular internalization, and trafficking,” *Small*, vol. 9, pp. 1521–1532, 2013.

[32] V. H. Nguyen and B. J. Lee, “Protein corona: a new approach for nanomedicine design,” *International Journal of Nanomedicine*, vol. 12, pp. 3137–3151, 2017.

[33] A. C. Anselmo, M. Zhang, S. Kumar et al., “Elasticity of nanoparticles influences their blood circulation, phagocytosis, endocytosis, and targeting,” *ACS Nano*, vol. 9, pp. 3169–3177, 2015.

[34] C. He, Y. Hu, L. Yin, C. Tang, and C. Yin, “Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles,” *Biomaterials*, vol. 31, pp. 3657–3666, 2010.

[35] J. V. Jokert, T. Lobovkina, R. N. Zare, and S. S. Gambhir, “Nanoparticle pegylation for imaging and therapy,” *Nanomedicine (London, England)*, vol. 6, pp. 715–728, 2011.

[36] Q. Zhang, D. Dehaim, Y. Zhang et al., “Neutrophil membrane-coated nanoparticles inhibit synovial inflammation and alleviate joint damage in inflammatory arthritis,” *Nature Nanotechnology*, vol. 13, pp. 1182–1190, 2018.

[37] J. Y. Oh, H. S. Kim, L. Palankumar et al., “Cloaking nanoparticles with protein corona shield for targeted drug delivery,” *Nature Communications*, vol. 9, p. 5458, 2018.

[38] P. Y. Liyanage, S. D. Hettiarachchi, Y. Zhou et al., “Nanoparticle-mediated targeted drug delivery for breast cancer treatment,” *Biochimica Et Biophysica Acta. Reviews on Cancer*, vol. 1871, pp. 419–433, 2019.

[39] P. Abasian, S. Ghanavati, S. Rahebi, S. Nouri Khorasani, and S. Khalili, “Polymeric nanocarriers in targeted drug delivery systems: a review,” *Polymers for Advanced Technologies*, vol. 31, pp. 2939–2954, 2020.

[40] X. Huang, P. K. Jain, I. H. El-Sayed, and M. A. El-Sayed, “Gold nanoparticles: interesting optical properties and recent applications in cancer diagnostics and therapy,” *Nanomedicine (London, England)*, vol. 2, pp. 681–693, 2007.

[41] X. Guo, Z. Wu, W. Li et al., “Appropriate size of magnetic nanoparticles for various bioapplications in cancer diagnostics and therapy,” *ACS Applied Materials & Interfaces*, vol. 8, pp. 3092–3106, 2016.

[42] R. van der Meel, E. Sulhaim, Y. Shi, F. Kiessling, W. J. M. Mulder, and T. Lammers, “Smart cancer nanomedicine,” *Nature Nanotechnology*, vol. 14, pp. 1007–1017, 2019.

[43] A. Aires, S. M. Ocampo, B. M. Simoes et al., “Multifunctionalized iron oxide nanoparticles for selective drug delivery to cd44-positive cancer cells,” *Nanotechnology*, vol. 27, article 065103, 2016.

[44] R. Dominguez-Rios, D. R. Sanchez-Ramirez, K. Ruiz-Saray et al., “Cisplatin-loaded plga nanoparticles for her2 targeted ovarian cancer therapy,” *Colloids and Surfaces. B, Biointerfaces*, vol. 178, pp. 199–207, 2019.

[45] N. L. Adolphi, K. S. Butler, D. M. Lovato et al., “Imaging of her2-targeted magnetic nanoparticles for breast cancer detection: comparison of squid-detected magnetic relaxometry and mri,” *Contrast Media & Molecular Imaging*, vol. 7, pp. 308–319, 2012.

[46] L. Xu, K. F. Pirollol, W. H. Tang, A. Rait, and E. H. Chang, “Transferrin-liposome-mediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts,” *Human Gene Therapy*, vol. 10, pp. 2941–2952, 1999.

[47] L. Han, Y. Ren, L. Long et al., “Inhibition of c6 glioma in vivo by combination chemotherapy of implantation of polymer wafer and intracarotid perfusion of transferrin-decorated nanoparticles,” *Oncology Reports*, vol. 27, pp. 121–128, 2012.

[48] S. A. Weiss, J. D. Wolchok, and M. Szol, “Immunotherapy of melanoma: facts and hopes,” *Clinical Cancer Research*, vol. 25, no. 17, pp. 5191–5201, 2019.

[49] K. Ganesh, Z. K. Stadler, A. Cercek et al., “Immunotherapy in colorectal cancer: rationale, challenges and potential,” *Nature Reviews. Gastroenterology & Hepatology*, vol. 16, pp. 361–375, 2019.

[50] S. Y. Gun, S. W. L. Lee, J. L. Siew, and S. C. Wong, “Targeting immune cells for cancer therapy,” *Redox Biology*, vol. 25, article 101174, 2019.

[51] R. M. Pallares, P. Choo, L. E. Cole, C. A. Mirkin, A. Lee, and T. W. Odom, “Manipulating immune activation of macrophages by tuning the oligonucleotide composition of gold nanoparticles,” *Bioconjugate Chemistry*, vol. 30, pp. 2032–2037, 2019.

[52] H. T. Nguyen, C. D. Phung, T. H. Tran et al., “Manipulating immune system using nanoparticles for an effective cancer treatment: combination of targeted therapy and checkpoint blockade mirna,” *Journal of Controlled Release*, vol. 329, pp. 524–537, 2021.

[53] J. S. He, S. J. Liu, Y. R. Zhang et al., “The application of and strategy for gold nanoparticles in cancer immunotherapy,” *Frontiers in Pharmacology*, vol. 12, article 687399, 2021.

[54] M. E. Aikins, C. Xu, and J. J. Moon, “Elasticity of nanoparticles influences their blood circulation, phagocytosis, endocytosis, and targeting,” *ACS Nano*, vol. 9, pp. 3169–3177, 2015.

[55] R. Wang, B. Song, J. Wu, Y. Zhang, A. Chen, and L. Shao, “Potential adverse effects of nanoparticles on the
reproductive system,” International Journal of Nanomedicine, vol. Volume 13, pp. 8487–8506, 2018.

[57] Z. Lyu, S. Ghoshdastidar, K. R. Rekha et al., “Developmental exposure to silver nanoparticles leads to long term gut dysbiosis and neurobehavioral alterations,” Scientific Reports, vol. 11, p. 6559, 2021.

[58] H. Mekaru, J. Lu, and F. Tamanini, “Development of mesoporous silica-based nanoparticles with controlled release capability for cancer therapy,” Advanced Drug Delivery Reviews, vol. 95, pp. 40–49, 2015.

[59] R. A. Siegel and M. J. Rathbone, Overview of Controlled Release Mechanisms, Springer, In Fundamentals and applications of controlled release drug delivery, 2012.

[60] C. W. Song, R. Griffin, and H. J. Park, Influence of Tumor Ph on Therapeutic Response, Springer, In Cancer drug resistance, 2006.

[61] D. C. Manatunga, R. M. de Silva, K. M. N. de Silva et al., “Ph responsive controlled release of anti-cancer hydrophobic drugs from sodium alginate and hydroxyapatite bi-coated iron oxide nanoparticles,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 117, pp. 29–38, 2017.

[62] Z. Xu, S. Liu, Y. Kang, and M. Wang, “Glutathione- and pH-responsive nonporous silica prodrug nanoparticles for controlled release and cancer therapy,” Nanoscale, vol. 7, pp. 5859–5868, 2015.

[63] H. J. Lee, S. E. Kim, I. K. Kwon et al., “Spatially mineralized self-assembled polymeric nanocarriers with enhanced robustness and controlled drug-releasing property,” Chem. Commun. (Camb.), vol. 46, pp. 377–379, 2010.

[64] S. Herrlich, S. Spieth, S. Messner, and R. Zengerle, “Osmotic micropumps for drug delivery,” Advanced Drug Delivery Reviews, vol. 64, pp. 1617–1627, 2012.

[65] N. A. Peppas, P. Bures, W. Leobandung, and H. Ichikawa, “Hydrogels in pharmaceutical formulations,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 50, pp. 27–46, 2000.

[66] L. Cabeza, G. Perazzoli, C. Mesas et al., “Nanoparticles in colorectal cancer therapy: latest in vivo assays, clinical trials, and patents,” AAPS PharmSciTech, vol. 21, p. 178, 2020.

[67] M. D’Acunto, P. Cioni, E. Gabellieri, and G. Presciutti, “Exploiting gold nanoparticles for diagnosis and cancer treatments,” Nanotechnology, vol. 32, article 192001, 2021.

[68] S. Siddique and J. C. L. Chow, “Gold nanoparticles for drug delivery and cancer therapy,” Applied Sciences-Basel, vol. 10, p. 3824, 2020.

[69] B. Pang, X. Yang, and Y. Xia, “Putting gold nanocages to work for optical imaging, controlled release and cancer theranostics,” Nanomedicine (London, England), vol. 11, pp. 1715–1728, 2016.

[70] A. Shakeri-Zadeh, H. Zareyi, R. Sheervailou, S. Laurent, H. Ghaznavi, and H. Samadian, “Gold nanoparticle-mediated bubbles in cancer nanotechnology,” Journal of Controlled Release, vol. 330, pp. 49–60, 2021.

[71] L. J. Desmond, A. N. Phan, and P. Gentile, “Critical overview on the green synthesis of carbon quantum dots and their application for cancer therapy,” Environmental Science: Nano, vol. 8, pp. 848–862, 2021.

[72] A. Alaghmandfard, O. Sedighi, N. Tabatabaei Rezaei et al., “Recent advances in the modification of carbon-based quantum dots for biomedical applications,” Materials Science & Engineering. C, Materials for Biological Applications, vol. 120, article 111756, 2021.

[73] H. Zhang, D. Yee, and C. Wang, “Quantum dots for cancer diagnosis and therapy: biological and clinical perspectives,” Nanomedicine (London, England), vol. 3, pp. 83–91, 2008.

[74] K. H. Wong, A. Lu, X. Chen, and Z. Yang, “Natural ingredient-based polymeric nanoparticles for cancer treatment,” Molecules, vol. 25, p. 3620, 2020.

[75] J. Meng, F. Q. Guo, H. Y. Xu, W. Liang, C. Wang, and X. D. Yang, “Combination therapy using co-encapsulated resveratrol and paclitaxel in liposomes for drug resistance reversal in breast cancer cells in vivo,” Scientific Reports, vol. 6, pp. 1–11, 2016.

[76] P. Yingchoncharoen, D. S. Kalinowski, and D. R. Richardson, “Lipid-based drug delivery systems in cancer therapy: what is available and what is yet to come,” Pharmaceutical Reviews, vol. 68, pp. 701–787, 2016.

[77] A. Rahiminejad, R. Dinarvand, B. Johari et al., “Preparation and investigation of indirubin-loaded sln nanoparticles and their anti-cancer effects on human glioblastoma u87mg cells,” Cell Biology International, vol. 43, pp. 2–11, 2019.

[78] F. Dilnawaz, “Multifunctional mesoporous silica nanoparticles for cancer therapy and imaging,” Current Medicinal Chemistry, vol. 26, pp. 5745–5763, 2019.

[79] C. Xu, C. Lei, and C. Yu, “Mesoporous silica nanoparticles for protein protection and delivery,” Frontiers in Chemistry, vol. 7, p. 290, 2019.

[80] S. Barui and V. Cauda, “Multimodal decorations of mesoporous silica nanoparticles for improved cancer therapy,” Pharmaceutics, vol. 12, p. 527, 2020.

[81] K. D. Weltmann and T. von Woedtke, “Plasma medicin-current state of research and medical application,” Plasma Physics and Controlled Fusion, vol. 59, article 014031, 2017.

[82] T. von Woedtke, A. Schmidt, S. Bekeschus, K. Wende, and K. D. Weltmann, “Plasma medicine: a field of applied redox biology,” In Vivo, vol. 33, no. 4, pp. 1011–1026, 2019.

[83] N. Y. Babaeva and M. J. Kushner, “Reactive fluxes delivered by dielectric barrier discharge filaments to slightly wounded skin,” Journal of Physics D: Applied Physics, vol. 46, article 025401, 2013.

[84] A. Schmidt-Bleker, S. A. Norberg, J. Winter et al., “Propagation mechanisms of guided streamers in plasma jets: the influence of electronegativity of the surrounding gas,” Plasma Sources Sci. T., vol. 24, 2015.

[85] S. Bekeschus, A. Lin, A. Fridman, K. Wende, and K. D. Weltmann, and V. Miller, “A comparison of floating-electrode dbd and pinjet: plasma parameters to achieve similar growth reduction in colon cancer cells under standardized conditions,” Plasma Chemistry and Plasma Processing, vol. 38, pp. 1–12, 2017.

[86] R. Clemens, E. Freund, D. Mrochen et al., “Gas plasma technology augments ovalbumin immunogenicity and ot-ii t cell activation conferring tumor protection in mice,” Adv Sci (Weinh), vol. 8, p. 2003395, 2021.

[87] S. Wenske, J. W. Lackmann, L. M. Busch, S. Bekeschus, T. von Woedtke, and K. Wende, “Reactive species driven oxidative modifications of peptides-tracing physical plasma liquid chemistry,” Journal of Applied Physics, vol. 129, 2021.
plasma-derived oxidants be transported via thiol group oxidation?,” *Clinical Plasma Medicine*, vol. 14, 2019.

[89] J. Striesow, J. W. Lackmann, Z. Ni et al., “Oxidative modification of skin lipids by cold atmospheric plasma (cap): a standardizable approach using rp-lc/ms(2) and di-esi/ms(2),” *Chemistry and Physics of Lipids*, vol. 226, article 104786, 2020.

[90] L. Guo, Y. Zhao, D. Liu et al., “Cold atmospheric-pressure plasma induces DNA-protein crosslinks through protein oxidation,” *Free Radical Research*, vol. 52, pp. 783–798, 2018.

[91] G. P. Bienert and F. Chaumont, “Aquaporin-facilitated transmembrane diffusion of hydrogen peroxide,” *Biochimica et Biophysica Acta*, vol. 1840, pp. 1596–1604, 2014.

[92] C. M. Wolff, J. F. Kolb, K. D. Weltmann, T. von Woedtke, and S. Bekeschus, “Combination treatment with cold physical plasma and pulsed electric fields augments ros production and cytotoxicity in lymphoma,” *Cancers (Basel)*, vol. 12, p. 845, 2020.

[93] H. Mahdikia, F. Saadati, E. Freund et al., “Gas plasma irradiation of breast cancers promotes immunogenicity, tumor reduction, and an abscopal effect in vivo,” *Oncoimmunology*, vol. 10, p. 1859731, 2021.

[94] X. Lu, G. V. Naidis, M. Laroussi, S. Reuter, D. B. Graves, and K. Ostrivok, “Reactive species in non-equilibrium atmospheric-pressure plasmas: generation, transport, and biological effects,” *Physics Reports-Review Section of Physics Letters*, vol. 630, pp. 1–84, 2016.

[95] S. Bekeschus, A. Schmidt, K.-D. Weltmann, and T. von Woedtke, “The plasma jet kinpen – a powerful tool for wound healing,” *Clinical Plasma Medicine*, vol. 4, pp. 19–28, 2016.

[96] H. Tanaka, S. Bekeschus, D. Yan, M. Hori, M. Keidar, and M. Laroussi, “Plasma-treated solutions (pts) in cancer therapy,” *Cancers (Basel)*, vol. 13, p. 1737, 2021.

[97] E. Freund, K. R. Liedtke, J. van der Linde et al., “Physical plasma-treated saline promotes an immunogenic phenotype in ct26 colon cancer cells in vitro and in vivo,” *Scientific Reports*, vol. 9, p. 634, 2019.

[98] E. Freund, L. Miebach, R. Clemen et al., “Large volume spark discharge and plasma jet-technology for generating plasma-oxidized saline targeting colon cancer in vitro and in vivo,” *Journal of Applied Physics*, vol. 129, 2021.

[99] S. Takeda, S. Yamada, N. Hattori et al., “Intraperitoneal administration of plasma-activated medium: proposal of a novel treatment option for peritoneal metastasis from gastric cancer,” *Annals of Surgical Oncology*, vol. 24, pp. 1188–1194, 2017.

[100] L. Lin and M. Keidar, “A map of control for cold atmospheric plasma jets: from physical mechanisms to optimizations. Applied,” *Physics Reviews*, vol. 8, 2021.

[101] K. Wende, T. von Woedtke, K. D. Weltmann, and S. Bekeschus, “Chemistry and biochemistry of cold physical plasma derived reactive species in liquids,” *Biological Chemistry*, vol. 400, pp. 19–38, 2018.

[102] L. I. Partecke, K. Evert, J. Haugk et al., “Tissue tolerant plasma (ttp) induces apoptosis in pancreatic cancer cells in vitro and in vivo,” *BMC Cancer*, vol. 12, 2012.

[103] D. B. Graves, “The emerging role of reactive oxygen and nitrogen species in redox biology and some implications for plasma applications to medicine and biology,” *Journal of Physics D: Applied Physics*, vol. 45, article 263001, 2012.

[104] J. Benedikt, M. Mokhtar Hefny, A. Shaw et al., “The fate of plasma-generated oxygen atoms in aqueous solutions: non-equilibrium atmospheric pressure plasmas as an efficient source of atomic o(aq),” *Physical Chemistry Chemical Physics*, vol. 20, pp. 12037–12042, 2018.

[105] S. Mohades, N. Barekzi, H. Razavi, V. Maruthamuthu, and M. Laroussi, “Temporal evaluation of the anti-tumor efficiency of plasma-activated media,” *Plasma Processes and Polymers*, vol. 13, pp. 1206–1211, 2016.

[106] A. Schmidt, G. Liebelt, F. Niessner, T. von Woedtke, and S. Bekeschus, “Gas plasma-spurred wound healing is accompanied by regulation of focal adhesion, matrix remodeling, and tissue oxygenation,” *Redox Biology*, vol. 38, article 101809, 2021.

[107] A. Schmidt, G. Liebelt, J. Striesow et al., “The molecular and physiological consequences of cold plasma treatment in murine skin and its barrier function,” *Free Radical Biology & Medicine*, vol. 161, pp. 32–49, 2020.

[108] A. Schmidt, F. Niessner, T. von Woedtke, and S. Bekeschus, “Hyperspectral imaging of wounds reveals augmented tissue oxygenation following cold physical plasma treatment in vivo,” *IEEE Transactions on Radiation and Plasma Medical Sciences*, vol. 5, pp. 412–419, 2021.

[109] A. Schmidt, S. Dietrich, A. Steuer et al., “Non-thermal plasma activates human keratinocytes by stimulation of antioxidant and phase ii pathways,” *The Journal of Biological Chemistry*, vol. 290, pp. 6731–6750, 2015.

[110] Y. M. Lee, W. He, and Y. C. Liou, “The redox language in neurodegenerative diseases: oxidative post-translational modifications by hydrogen peroxide,” *Cell Death & Disease*, vol. 12, p. 58, 2021.

[111] S. I. Bibli and I. Fleming, “Oxidative post translational modifications: a focus on cysteine s-sulfhydration and the regulation of endothelial fitness,” *Antioxidants & Redox Signaling*, 2021.

[112] A. Lermant and C. E. Murdoch, “Cysteine glutathionylation acts as a redox switch in endothelial cells,” *Antioxidants (Basel)*, vol. 8, 2019.

[113] H. Sies, “On the history of oxidative stress: concept and some aspects of current development,” *Current Opinion in Toxicology*, vol. 7, pp. 122–126, 2018.

[114] H. Y. Lee, J. H. Choi, J. W. Hong, G. C. Kim, and H. J. Lee, “Comparative study of the ar and he atmospheric pressure plasmas on e-cadherin protein regulation for plasma-mediated transdermal drug delivery,” *Journal of Physics D: Applied Physics*, vol. 51, 2018.

[115] R. Bussiahn, N. Lembke, R. Gesche, T. von Woedtke, and K.-D. Weltmann, “Plasma sources for biomedical applications,” *Hyg. Med.*, vol. 38, pp. 212–216, 2013.

[116] N. Y. Babaeva and M. J. Kushner, “Intracellular electric fields produced by dielectric barrier discharge treatment of skin,” *Journal of Physics D: Applied Physics*, vol. 43, article 185206, 2010.

[117] T. Darny, J. M. Pouvesle, V. Puech, C. Douat, S. Dozias, and N. Y. Babaeva, “Temporal evaluation of the anti-tumor efficiency of plasma-activated media,” *Anticancer Research*, vol. 38, no. 10, pp. 5655–5663, 2018.
[119] S. Bekeschus, J. Moritz, I. Helfrich et al., ”Ex vivo exposure of human melanoma tissue to cold physical plasma elicits apoptosis and modulates inflammation,” Applied Sciences, vol. 10, 2020.

[120] M. Adhikari, N. Kaushik, B. Ghimire et al., ”Cold atmospheric plasma and silymarin nanoemulsion synergistically inhibits human melanoma tumorigenesis via targeting hgf-c-met downstream pathway,” Cell Communication and Signaling: CCS, vol. 17, p. 52, 2019.

[121] N. Yoshikawa, W. Liu, K. Nakamura et al., ”Plasma-activated medium promotes autophagic cell death along with alteration of the mitor pathway,” Scientific Reports, vol. 10, p. 16144, 2020.

[122] E. H. Choi, B. Chang, J. H. Choi, K. S. Kim, and A. Bisag, C. Bucci, S. Coluccelli et al., ”Plasma-activated medium promotes autophagic cell death along with alteration of the mitor pathway,” Cell Communication and Signaling: CCS, vol. 17, p. 52, 2019.

[123] M. Bourdans, Y. Jeanson, M. Taurand et al., ”Short exposure to cold atmospheric plasma induces senescence in human skin fibroblasts and adipose mesenchymal stromal cells,” Scientific Reports, vol. 9, p. 8671, 2019.

[124] S. Arndt, E. Wacker, Y. F. Li et al., ”Cold atmospheric plasma, a new strategy to induce senescence in melanoma cells,” Experimental Dermatology, vol. 22, pp. 284–289, 2013.

[125] S. Schneider, L. Gebhardt, S. Arndt et al., ”Cold atmospheric plasma causes a calcium influx in melanoma cells triggering cap-induced senescence,” Scientific Reports, vol. 8, p. 10048, 2018.

[126] S. B. Karki, T. T. Gupta, E. Yildirim-Ayan, K. M. Eisenmann, and H. Ayan, ”Miniature non-thermal plasma induced cell cycle arrest and apoptosis in lung carcinoma cells,” Plasma Chemistry and Plasma Processing, vol. 40, pp. 99–117, 2019.

[127] M. Aswini, S. Suresh, K. Rajasekar, V. Aravindan, and E. Robert, ”Plasma-activated medium induces apoptosis in chemotherapy-resistant ovarian cancer cells: high selectivity and synergy with carboplatin,” Plasma Processes and Polymers, vol. 18, no. 9, p. 2100074, 2021.

[128] M. Khalili, L. Daniels, A. Lin et al., ”Non-thermal plasma-induced immunogenic cell death in cancer: a topical review,” Journal of Physics D: Applied Physics, vol. 52, 2019.

[129] S. Bekeschus, R. Clemen, F. Niessner, S. K. Sagwal, E. Freund, and K. Ostrikov, ”Medical gas plasma jet technology targets murine melanoma in an immunogenic fashion,” Adv Sci (Weinh), vol. 7, p. 1903438, 2020.

[130] M. Khalili, L. Daniels, A. Lin et al., ”Non-thermal plasma-stimulated wound healing: evidence and mechanisms,” Redox Biology, vol. 46, article 102116, 2021.

[131] A. Bisag, C. Bucci, S. Coluccelli et al., ”Plasma-activated ringer’s lactate solution displays a selective cytotoxic effect on ovarian cancer cells,” Cancers (Basel), vol. 12, 2020.

[132] C. Canal, R. Fontelo, I. Hamouda, J. Guillem-Marti, U. Cveilbar, and M. P. Ginebra, ”Plasma-induced selectivity in bone cancer cells death,” Free Radical Biology & Medicine, vol. 110, pp. 72–80, 2017.

[133] B. S. Kwon, E. H. Choi, B. Chang, J. H. Choi, K. S. Kim, and H. K. Park, ”Selective cytotoxic effect of non-thermal micro-dbd plasma,” Physical Biology, vol. 13, article 056001, 2016.

[134] D. Yan, H. Xiao, W. Zhu et al., ”The role of aquaporins in the anti-glioblastoma capacity of the cold plasma-stimulated medium,” Journal of Physics D: Applied Physics, vol. 50, 2017.

[135] M. Yusupov, D. Y. Yan, R. M. Cordeiro, and A. Bogaerts, ”Atomic scale simulation of h2o2 permeation through aquaporin: toward the understanding of plasma cancer treatment,” Journal of Physics D: Applied Physics, vol. 51, 2018.

[136] F. de Meyer and B. Smit, ”Effect of cholesterol on the structure of a phospholipid bilayer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, pp. 3654–3658, 2009.

[137] D. Trachootham, J. Alexandre, and P. Huang, ”Targeting cancer cells by ros-mediated mechanisms: a radical therapeutic approach?,” Nature Reviews Drug Discovery, vol. 8, pp. 579–591, 2009.

[138] H.-R. Metelmann, C. Seebauer, V. Miller et al., ”Clinical experience with cold plasma in the treatment of locally advanced head and neck cancer,” Clinical Plasma Medicine, vol. 9, pp. 6–13, 2018.

[139] C. Schneider, L. Gebhardt, S. Arndt et al., ”Side effects in cold plasma treatment of advanced oral cancer—clinical data and biological interpretation,” Clinical Plasma Medicine, vol. 10, pp. 9–15, 2018.

[140] M. Bourdans, Y. Jeanson, M. Taurand et al., ”Visible tumor surface response to physical plasma and apoptotic cell kill in head and neck cancer,” Journal of Cranio-Maxillo-Facial Surgery, vol. 44, pp. 1445–1452, 2016.

[141] M. Khalili, L. Daniels, A. Lin et al., ”Non-thermal plasma-induced immunogenic cell death in cancer: a topical review,” Journal of Physics D: Applied Physics, vol. 52, 2019.

[142] S. Bekeschus, R. Clemen, F. Niessner, S. K. Sagwal, E. Freund, and A. Schmidt, ”Medical gas plasma jet technology targets murine melanoma in an immunogenic fashion,” Adv Sci (Weinh), vol. 7, p. 1903438, 2020.

[143] M. Khalili, L. Daniels, A. Lin et al., ”Non-thermal plasma-stimulated wound healing: evidence and mechanisms,” Redox Biology, vol. 46, article 102116, 2021.

[144] A. Praetorius, R. Arvidsson, S. Molander, and M. Scheringer, ”Facing complexity through informed simplifications: a research agenda for aquatic exposure assessment of nanoparticles,” Environmental Science-Processes & Impacts, vol. 15, pp. 161–168, 2013.

[145] M. G. Kong, M. Keidar, and K. Ostrikov, ”Plasmas meet nanoparticles—where synergies can advance the frontier of medicine,” Journal of Physics D: Applied Physics, vol. 44, article 174018, 2011.

[146] J. Lademann, A. Patzelt, H. Richter et al., ”Nanoencapsulation of Paclitaxel-loaded core–shell magnetic nanoparticles and cold atmospheric plasma inhibit non-small cell lung cancer growth,” ACS Applied Materials & Interfaces, vol. 10, pp. 43462–43471, 2018.

[147] X. Dai, Z. Zhang, J. Zhang, and K. Ostrikov, ”Dosing the key to precision plasma oncology,” Plasma Processes and Polymers, vol. 17, no. 10, p. 1900178, 2020.

[148] M. Arvidsson, S. Molander, and M. Scheringer, ”Facing complexity through informed simplifications: a research agenda for aquatic exposure assessment of nanoparticles,” Environmental Science-Processes & Impacts, vol. 15, pp. 161–168, 2013.

[149] M. G. Kong, M. Keidar, and K. Ostrikov, ”Plasmas meet nanoparticles—where synergies can advance the frontier of medicine,” Journal of Physics D: Applied Physics, vol. 44, article 174018, 2011.

[150] J. Lademann, A. Patzelt, H. Richter et al., ”Nanoencapsulation of Paclitaxel-loaded core–shell magnetic nanoparticles and cold atmospheric plasma inhibit non-small cell lung cancer growth,” ACS Applied Materials & Interfaces, vol. 10, pp. 43462–43471, 2018.

[151] X. Dai, Z. Zhang, J. Zhang, and K. Ostrikov, ”Dosing the key to precision plasma oncology,” Plasma Processes and Polymers, vol. 17, no. 10, p. 1900178, 2020.

[152] M. Arvidsson, S. Molander, and M. Scheringer, ”Facing complexity through informed simplifications: a research agenda for aquatic exposure assessment of nanoparticles,” Environmental Science-Processes & Impacts, vol. 15, pp. 161–168, 2013.

[153] M. G. Kong, M. Keidar, and K. Ostrikov, ”Plasmas meet nanoparticles—where synergies can advance the frontier of medicine,” Journal of Physics D: Applied Physics, vol. 44, article 174018, 2011.

[154] J. Lademann, A. Patzelt, H. Richter et al., ”Nanoencapsulation of Paclitaxel-loaded core–shell magnetic nanoparticles and cold atmospheric plasma inhibit non-small cell lung cancer growth,” ACS Applied Materials & Interfaces, vol. 10, pp. 43462–43471, 2018.

[155] X. Dai, Z. Zhang, J. Zhang, and K. Ostrikov, ”Dosing the key to precision plasma oncology,” Plasma Processes and Polymers, vol. 17, no. 10, p. 1900178, 2020.

[156] M. Arvidsson, S. Molander, and M. Scheringer, ”Facing complexity through informed simplifications: a research agenda for aquatic exposure assessment of nanoparticles,” Environmental Science-Processes & Impacts, vol. 15, pp. 161–168, 2013.
physical plasma elicits melanoma cell death via upregulation of slc22a16," Cell Death & Disease, vol. 9, p. 1179, 2018.

[151] K. R. Liedtke, E. Freund, M. Hermes et al., "Gas plasma-conditioned ringer’s lactate enhances the cytotoxic activity of cisplatin and gemcitabine in pancreatic cancer in vitro and in ovo," Cancers (Basel), vol. 12, p. 123, 2020.

[152] G. Busco, E. Robert, N. Chettouh-Hammas, J. M. Pouveles, and C. Grillon, "The emerging potential of cold atmospheric plasma in skin biology," Free Radical Biology & Medicine, vol. 161, pp. 290–304, 2020.

[153] T. Kaneko, S. Sasaki, Y. Yokari, S. Horiuchi, R. Honda, and M. Kanzaki, "Improvement of cell membrane permeability using a cell-solution electrode for generating atmospheric-pressure plasma," Biointerphases, vol. 10, article 029521, 2015.

[154] X. Q. Cheng, W. Murphy, N. Reeck et al., "Synergistic effect of gold nanoparticles and cold plasma on glioblastoma cancer therapy," Journal of Physics D: Applied Physics, vol. 47, article 335402, 2014.

[155] P. Shaw, N. Kumar, D. Hammerschmid, A. Privat-Maldonado, S. Dewilde, and A. Bogaerts, "Synergistic effects of melittin and plasma treatment: a promising approach for cancer therapy," Cancers (Basel), vol. 11, 2019.

[156] P. Lukes, E. Dolezalova, I. Sisrova, and M. Clupek, "Aqueous-phase chemistry and bactericidal effects from an air discharge plasma in contact with water: evidence for the formation of peroxyxynitrite through a pseudo-second-order post-discharge reaction of h2o2and hno2," Plasma Sources Sci. T., vol. 23, article 015019, 2014.

[157] Y. Dai, C. Xu, X. Sun, and X. Chen, "Nanoparticle design strategies for enhanced anticancer therapy by exploiting the tumour microenvironment," Chemical Society Reviews, vol. 46, pp. 3830–3852, 2017.

[158] G. Taneja, A. Sud, N. Pendse, B. Panigrahi, A. Kumar, and A. K. Sharma, "Nano-medicine and vascular endothelial dys-function: options and delivery strategies," Cardiovascular Toxicology, vol. 19, pp. 1–12, 2019.

[159] N. K. Kaushik, N. Kaushik, K. C. Yoo et al., "Low doses of peg-coated gold nanoparticles sensitize solid tumors to cold plasma by blocking the p38akt-driven signaling axis to suppress cellular transformation by inhibiting growth and errit," Biomaterials, vol. 87, pp. 118–130, 2016.

[160] Z. He, K. Liu, E. Manaloto et al., "Cold atmospheric plasma induces atp-dependent endocytosis of nanoparticles and synergistic u373mg cancer cell death," Scientific Reports, vol. 8, p. 5298, 2018.

[161] X. Q. Cheng, K. Rajjoub, J. Sherman et al., "Cold plasma accelerates the uptake of gold nanoparticles into glioblastoma cells," Plasma Processes and Polymers, vol. 12, pp. 1364–1369, 2015.

[162] G. C. Kim, G. J. Kim, S. R. Park et al., "Air plasma coupled with antibody-conjugated nanoparticles: a new weapon against cancer," Journal of Physics D: Applied Physics, vol. 42, article 032005, 2009.

[163] P. Jawaad, M. U. Rehman, Q. L. Zhao et al., "Small size gold nanoparticles enhance apoptosis-induced by cold atmospheric plasma via depletion of intracellular gsh and modification of oxidative stress," Cell Death Discovery, vol. 6, p. 83, 2020.

[164] B. B. Choi, M. S. Kim, U. K. Kim, J. W. Hong, H. J. Lee, and G. C. Kim, "Targeting neu protein in melanoma cells with non-thermal atmospheric pressure plasma and gold nanoparticles," Journal of Biomedical Nanotechnology, vol. 11, pp. 900–905, 2015.

[165] B. B. R. Choi, J. H. Choi, J. W. Hong et al., "Selective killing of melanoma cells with non-thermal atmospheric pressure plasma and p-fak antibody conjugated gold nanoparticles," International Journal of Medical Sciences, vol. 14, pp. 1101–1109, 2017.

[166] S. Bekeschus, "Combined toxicity of gas plasma treatment and nanoparticles exposure in melanoma cells in vitro," Nanomaterials (Basel), vol. 11, 2021.

[167] Z. He, K. Liu, L. Scally et al., "Cold atmospheric plasma stimulates clathrin-dependent endocytosis to repair oxidised membrane and enhance uptake of nanomaterial in glioblastoma multiforme cells," Scientific Reports, vol. 10, p. 6985, 2020.

[168] A. Jalili, S. Irani, and R. Mirfakhraie, "Combination of cold atmospheric plasma and iron nanoparticles in breast cancer: gene expression and apoptosis study," Oncotargets and Therapy, vol. 9, pp. 5911–5917, 2016.

[169] W. Li, H. Yu, D. Ding et al., "Cold atmospheric plasma and iron oxide-based magnetic nanoparticles for synergetic lung cancer therapy," Free Radical Biology & Medicine, vol. 130, pp. 71–81, 2019.

[170] K. W. Witwer and J. Wolfram, "Extracellular vesicles versus synthetic nanoparticles for drug delivery," Nature Reviews Materials, vol. 6, pp. 103–106, 2021.

[171] J. Canady, S. Gordon, T. Zhuang et al., "Cold atmospheric plasma (cap) combined with chemo-radiation and cytoreductive surgery: the first clinical experience for stage iv metastatic colon cancer," in Comprehensive Clinical Plasma Medicine: Cold Physical Plasma for Medical Application, H.-R. Metelmann, T. Woedtke, and K.-D. Woltmann, Eds., pp. 163–183, Springer International Publishing, Cham, 2018.

[172] M. Arisi, S. Soglia, E. Guasco Pisani et al., "Cold atmospheric plasma (cap) for the treatment of actinic keratosis and skin field carcinization: clinical and high-frequency ultrasound evaluation," Dermatology and Therapy, vol. 11, pp. 855–866, 2021.

[173] G. Daeschlein, A. Arnold, S. Lutze et al., "Treatment of recalcitrant actinic keratosis (ak) of the scalp by cold atmospheric plasma," Cogent Medicine, vol. 4, p. 1412903, 2017.

[174] P. C. Friedman, V. Miller, G. Fridman, A. Lin, and A. Fridman, "Successful treatment of actinic keratoses using nonthermal atmospheric pressure plasma: a case series," Journal of the American Academy of Dermatology, vol. 76, pp. 349–350, 2017.

[175] M. Wirtz, I. Stoffels, J. Dissemond, D. Schadendorf, and A. Roesch, "Actinic keratoses treated with cold atmospheric plasma," Journal of the European Academy of Dermatology and Venereology, vol. 32, pp. e37–e39, 2018.

[176] J. Shi, P. W. Kantoff, R. Wooster, and O. C. Farokhzad, "Cancer nanomedicine: Progress, challenges and opportunities," Nature Reviews. Cancer, vol. 17, pp. 20–37, 2017.

[177] N. Bertrand, J. Wu, X. Xu, N. Kamaly, and O. C. Farokhzad, "Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology," Advanced Drug Delivery Reviews, vol. 66, pp. 2–25, 2014.

[178] A. Albanese, A. K. Lam, E. A. Sykes, J. V. Rocheleau, and W. C. Chan, "Tumour-on-a-chip provides an optical window
into nanoparticle tissue transport,” Nature Communications, vol. 4, p. 2718, 2013.

[179] M. J. Mitchell, M. M. Billingsley, R. M. Haley, M. E. Wechsler, N. A. Peppas, and R. Langer, “Engineering precision nanoparticles for drug delivery,” Nature Reviews. Drug Discovery, vol. 20, pp. 101–124, 2021.

[180] R. Iyer, T. Nguyen, D. Padanilam et al., “Glutathione-responsive biodegradable polyurethane nanoparticles for lung cancer treatment,” Journal of Controlled Release, vol. 321, pp. 363–371, 2020.

[181] K. Recznyska, M. Marszalek, A. Zarzycki et al., “Superparamagnetic iron oxide nanoparticles modified with silica layers as potential agents for lung cancer treatment,” Nanomaterials (Basel), vol. 10, p. 1076, 2020.

[182] Y. Song, B. Zhou, X. Du et al., “Folic acid (fa)-conjugated mesoporous silica nanoparticles combined with mrp-1 sirna improves the suppressive effects of myricetin on non-small cell lung cancer (nsclc),” Biomedicine & Pharmacotherapy, vol. 125, article 109561, 2020.

[183] R. Tanino, Y. Amano, T. Tong et al., “Anticancer activity of zno nanoparticles against human small-cell lung cancer in an orthotopic mouse model,” Molecular Cancer Therapeutics, vol. 19, pp. 502–512, 2020.

[184] H. Wang, F. K. Zhang, H. Y. Wen et al., “Tumor- and mitochondria-targeted nanoparticles eradicate drug resistant lung cancer through mitochondrial pathway of apoptosis,” Journal of Nanobiotechnology, vol. 18, pp. 1–21, 2020.

[185] Y. Wang, H. Yu, S. Wang et al., “Targeted delivery of quercetin by nanoparticles based on chitosan sensitizing paclitaxel-resistant lung cancer cells to paclitaxel,” Materials Science & Engineering. C, Materials for Biological Applications, vol. 119, article 111442, 2021.

[186] X. Wang, V. Parvathaneni, S. K. Shukla et al., “Inhalable resveratrol-cycloextrin complex loaded biodegradable nanoparticles for enhanced efficacy against non-small cell lung cancer,” International Journal of Biological Macromolecules, vol. 164, pp. 638–650, 2020.

[187] B. Vaidya, N. S. Kulkarni, S. K. Shukla et al., “Development of inhalable quinacrine loaded bovine serum albumin modified cationic nanoparticles: repurposing quinacrine for lung cancer therapeutics,” International Journal of Pharmaceutics, vol. 577, article 118995, 2020.

[188] M. Landgraf, C. A. Lahr, I. Kaur et al., “Targeted camptothecin delivery via silicon nanoparticles reduces breast cancer metastasis,” Biomaterials, vol. 240, article 119791, 2020.

[189] M. Sharifi, S. Jafari, A. Hasan et al., “Antimetastatic activity of lactoferrin-coated mesoporous maghemite nanoparticles in breast cancer enabled by combination therapy,” ACS Biomaterials Science & Engineering, vol. 6, pp. 3574–3584, 2020.

[190] K. Xiong, Y. Zhang, Q. Wen et al., “Co-delivery of paclitaxel and curcumin by biodegradable polymeric nanoparticles for breast cancer chemotherapy,” International Journal of Pharmaceutics, vol. 589, article 119875, 2020.

[191] J. Lei, H. Wang, D. Zhu, Y. Wan, and L. Yin, “Combined effects of avasimibe immunotherapy, doxorubicin chemotherapy, and metal-organic frameworks nanoparticles on breast cancer,” Journal of Cellular Physiology, vol. 235, pp. 4814–4823, 2020.

[192] M. Mughees, S. Wajid, and M. Samim, “Cytotoxic potential of artemisia absinthium extract loaded polymeric nanoparticles against breast cancer cells: insight into the protein targets,” International Journal of Pharmaceutics, vol. 586, article 119583, 2020.

[193] Q. Jiang, M. Zhang, Q. Sun, D. Yin, Z. Xuan, and Y. Yang, “Enhancing the antitumor effect of doxorubicin with photosensitive metal-organic framework nanoparticles against breast cancer,” Molecular Pharmaceutics, vol. 18, no. 8, pp. 3026–3036, 2021.

[194] B. Toubhans, S. A. Gazze, C. Bissardon et al., “Selenium nanoparticles trigger alterations in ovarian cancer cell biomechanics,” Nanomedicine, vol. 29, article 102258, 2020.

[195] N. Brandhonnerie, Y. Boucoud, A. Verger et al., “Molybdenum cluster loaded plga nanoparticles as efficient tools against epithelial ovarian cancer,” International Journal of Pharmaceutics, vol. 592, article 120079, 2021.

[196] V. Ramalingam, M. Harshavardhan, S. Dinesh Kumar, and S. Malathi devi, “Wet chemical mediated hematite α-fe2o3 nanoparticles synthesis: preparation, characterization and anticancer activity against human metastatic ovarian cancer,” Journal of Alloys and Compounds, vol. 834, article 155118, 2020.

[197] A. I. Fraguras-Sanchez, A. I. Torres-Suarez, M. Cohen et al., “Plga nanoparticles for the intraperitoneal administration of cdb in the treatment of ovarian cancer: in vitro and in ovo assessment,” Pharmaceutics, vol. 12, 2020.

[198] M. Fathi, J. Barar, H. Erfan-Niya, and Y. Omidi, “Methotrexate-conjugated chitosan-grafted ph- and thermo-responsive magnetic nanoparticles for targeted therapy of ovarian cancer,” International Journal of Biological Macromolecules, vol. 154, pp. 1175–1184, 2020.

[199] Q. Pan, J. Tian, H. Zhu et al., “Tumor-targeting polycaprolactone nanoparticles with codelivery of paclitaxel and ir780 for combinational therapy of drug-resistant ovarian cancer,” ACS Biomaterials Science & Engineering, vol. 6, pp. 2175–2185, 2020.

[200] Z. Yu, X. Li, J. Duan, and X. D. Yang, “Targeted treatment of colon cancer with aptamer-guided albumin nanoparticles loaded with docetaxel,” International Journal of Nanomedicine, vol. 15, pp. 6737–6748, 2020.

[201] G. Chen, Y. Zhao, Y. Xu, C. Zhu, T. Liu, and K. Wang, “Chitosan nanoparticles for oral photothermally enhanced photodynamic therapy of colon cancer,” International Journal of Pharmaceutics, vol. 589, article 119763, 2020.

[202] X. L. Liang, M. Chen, P. Bhattacharai, S. Hameed, and Z. F. Dai, “Perfluorocarbon@porphyrin nanoparticles for tumor hypoxia relief to enhance photodynamic therapy against liver metastasis of colon cancer,” ACS Nano, vol. 14, pp. 13569–13583, 2020.

[203] D. Acharya, S. Satapathy, P. Somu, U. K. Parida, and G. Mishra, “Apoptotic effect and anticancer activity of biosynthesized silver nanoparticles from marine algae chaetomorpha linum extract against human colon cancer cell hct-116,” Biological Trace Element Research, vol. 199, pp. 1812–1822, 2021.

[204] Y. Liu, J. T. Zhao, J. L. Jiang, F. F. Chen, and X. D. Fang, “Doxorubicin delivered using nanoparticles camouflaged with mesenchymal stem cell membranes to treat colon cancer,” International Journal of Nanomedicine, vol. 15, pp. 2873–2884, 2020.

[205] V. K. Chaturvedi, N. Yadav, N. K. Rai et al., “Pleurotus sajor-caju-mediated synthesis of silver and gold nanoparticles active against colon cancer cell lines: a new era of herbonanocutetics,” Molecules, vol. 25, p. 3091, 2020.
[206] K. AbouAitah, A. Stefanek, I. M. Higazy et al., “Effective targeting of colon cancer cells with piperine natural anticancer produgs using functionalized clusters of hydroxyapatite nanoparticles,” Pharmacuetics, vol. 12, p. 70, 2020.

[207] P. P. Wu, Q. Zhou, H. Y. Zhu, Y. Zhuang, and J. Bao, “Enhanced antitumor efficacy in colon cancer using egf functionalized plga nanoparticles loaded with 5-fluorouracil and perfluorocarbon,” BMC Cancer, vol. 20, pp. 1–10, 2020.

[208] I. Sur-Erdem, K. Muslu, N. Pinarbasi et al., “Trail-conjugated silver nanoparticles sensitize glioblastoma cells to trigger regulating chkl1 in the DNA repair pathway,” Neurological Research, vol. 42, pp. 1061–1069, 2020.

[209] V. M. Lu, T. R. Jue, and K. L. McDonald, “Cytoxic lanthanum oxide nanoparticles sensitize glioblastoma cells to radiation therapy and temozolomide: an in vitro rationale for translational studies,” Scientific Reports, vol. 10, p. 18156, 2020.

[210] S. Sheykhdadeh, M. Luo, B. Peng et al., “Transferrin-targeted porous silicon nanoparticles reduce glioblastoma cell migration across tight extracellular space,” Scientific Reports, vol. 10, p. 23220, 2020.

[211] N. Prabhakar, J. Merisaari, V. Le Joncour et al., “Enhanced antitumor efficacy in colon cancer using egf functionalized plga nanoparticles loaded with 5-fluorouracil and perfluorocarbon,” BMC Cancer, vol. 20, pp. 1–10, 2020.

[212] M. Norouzi, V. Yathindranath, J. A. Thliveris, and D. W. Miller, “Doxorubicin-loaded iron oxide nanoparticles for glioblastoma therapy: a combinational approach for enhanced delivery of nanoparticles,” Scientific Reports, vol. 10, p. 11292, 2020.

[213] J. V. Gregory, P. Kadiyala, R. Doherty et al., “Systemic brain tumor delivery of synthetic protein nanoparticles for glioblastoma therapy,” Nature Communications, vol. 11, p. 5687, 2020.

[214] M. Norouzi, V. Yathindranath, J. A. Thliveris, and D. W. Miller, “Salinomycin-loaded iron oxide nanoparticles for glioblastoma therapy,” Nanomaterials (Basel), vol. 10, p. 477, 2020.

[215] H. Han, Y. Hou, X. Chen et al., “Metformin-induced stromal depletion to enhance the penetration of gemcitabine-loaded magnetic nanoparticles for pancreatic cancer targeted therapy,” Journal of the American Chemical Society, vol. 142, pp. 4944–4954, 2020.

[216] X. Chen, F. Jia, Y. Li et al., “Nitric oxide-induced stromal depletion for improved nanoparticle penetration in pancreatic cancer treatment,” Biomaterials, vol. 246, article 119999, 2020.

[217] S. Bao, H. Zheng, J. Ye et al., “Dual targeting egrf and stat3 with erlotinib and alantolactone co-loaded plga nanoparticles for pancreatic cancer treatment,” Frontiers in Pharmacology, vol. 12, article 625084, 2021.

[218] L. Liu, P. Kshirsagar, J. Christiansen et al., “Polyanhydride nanoparticles stabilize pancreatic cancer antigen muca8beta,” Journal of Biomedical Materials Research. Part A, vol. 109, pp. 893–902, 2021.

[219] K. O. Affram, T. Smith, E. Ofori et al., “Cytotoxic effects of gemcitabine-loaded solid lipid nanoparticles in pancreatic cancer cells,” Journal of Drug Delivery Science and Technology, vol. 55, article 101374, 2020.

[220] T. Zhang, Z. Q. Jiang, L. B. Chen et al., “Pcn-fel(iii)-ptx nanoparticles for mri guided high efficiency chemo-photodynamic therapy in pancreatic cancer through alleviating tumor hypoxia,” Nano Research, vol. 13, pp. 273–281, 2020.

[221] X. Kesse, A. Adam, S. Begin-Colin et al., “Elaboration of superparamagnetic and bioactive multicore-shell nanoparticles (gamma-fe2o3@si02-cao): a promising material for bone cancer treatment,” ACS Applied Materials & Interfaces, vol. 12, pp. 47820–47830, 2020.

[222] J. Cheng, X. Wang, L. Qiu et al., “Green synthesized zinc oxide nanoparticles regulates the apoptotic expression in bone cancer cells mg-63 cells,” Journal of Photochemistry and Photobiology. B, vol. 202, article 111644, 2020.

[223] A. El-Fiqi and H. W. Kim, “Iron ions-releasing mesoporous bioactive glass ultrasmall nanoparticles designed as ferroptosis-based bone cancer nanotherapeutics: ultrasensitive coupled sol-gel synthesis, properties and iron ions release,” Materials Letters, vol. 294, article 129759, 2021.

[224] D. Ahmadi, M. Zarei, M. Rahimi et al., “Preparation and in-vitro evaluation of ph-responsive cationic cyclodextrin coated magnetic nanoparticles for delivery of methotrexate to the saos-2 bone cancer cells,” Journal of Drug Delivery Science and Technology, vol. 57, article 101584, 2020.

[225] S. B. Bai, Y. Cheng, D. Z. Liu et al., “Bone-targeted pamam nanoparticle to treat bone metastases of lung cancer,” Nanomedicine (London, England), vol. 15, pp. 833–849, 2020.

[226] Y. Pang, Y. Fu, C. Li et al., “Metal-organic framework nanoparticles for ameliorating breast cancer-associated osteolysis,” Nano Letters, vol. 20, pp. 829–840, 2020.

[227] P. Sonkusre, “Specificity of biogenic selenium nanoparticles for prostate cancer therapy with reduced risk of toxicity: an in vitro and in vivo study,” Frontiers in Oncology, vol. 9, p. 1541, 2019.

[228] Y. Q. Fang, S. X. Lin, F. Yang, J. Situ, S. D. Lin, and Y. Luo, “Aptamer-conjugated multifunctional polymeric nanoparticles as cancer-targeted, mri-ultrasensitive drug delivery systems for treatment of castration-resistant prostate cancer,” BioMed Research International, vol. 2020, 2020.

[229] M. Soll, Q. C. Chen, B. Zhitomirsky et al., “Protein-coated corrole nanoparticles for the treatment of prostate cancer cells,” Cell Death Discovery, vol. 6, p. 67, 2020.

[230] Y. Chen, Y. Deng, C. Zhu, and C. Xiang, “Anti prostate cancer therapy: aptamer-functionalized, curcumin and cabazitaxel co-delivered, tumor targeted lipid-polymer hybrid nanoparticles,” Biomedicine & Pharmacotherapy, vol. 127, article 110181, 2020.

[231] D. Du, H. J. Fu, W. W. Ren, X. L. Li, and L. H. Guo, “Psa targeted dual-modality manganese oxide-mesoporous silica nanoparticles for prostate cancer imaging,” Biomedicine & Pharmacotherapy, vol. 121, article 109614, 2020.

[232] M. Emanet Ciofani, Ö. Şen, and M. Çulha, “Hexagonal boron nitride nanoparticles for prostate cancer treatment,” ACS Applied Nano Materials, vol. 3, pp. 2364–2372, 2020.

[233] E. Kozenkova, K. Levada, M. V. Efremova et al., “Multifunctional fe3o4- au nanoparticles for the mri diagnosis and potential treatment of liver cancer,” Nanomaterials (Basel), vol. 10, p. 1646, 2020.

[234] S. Li, P. E. Saw, C. Lin et al., “Redox-responsive polyprodrug nanoparticles for targeted sirna delivery and synergistic liver cancer therapy,” Biomaterials, vol. 234, article 119760, 2020.
[235] K. Ishiguro, I. K. Yan, L. Lewis-Tuffin, and T. Patel, “Targeting liver cancer stem cells using engineered biological nanoparticles for the treatment of hepatocellular cancer,” *Hepatology Communications*, vol. 4, pp. 298–313, 2020.

[236] J. Luo, T. Gong, and L. Ma, “Chondroitin-modified lipid nanoparticles target the golgi to degrade extracellular matrix for liver cancer management,” *Carbohydrate Polymers*, vol. 249, article 116887, 2020.

[237] Y. N. Han, B. Hu, M. Y. Wang et al., “Ph-sensitive tumor-targeted hyperbranched system based on glycogen nanoparticles for liver cancer therapy,” *Applied Materials Today*, vol. 18, article 100521, 2020.

[238] M. Suleman and S. Riaz, “In silico study of hyperthermia treatment of liver cancer using core-shell cofe2o4@mmfe2o4 magnetic nanoparticles,” *Journal of Magnetism and Magnetic Materials*, vol. 498, article 166143, 2020.

[239] Z. Ding, D. Wang, W. Shi et al., “In vivo targeting of liver cancer with tissue- and nuclei-specific mesoporous silica nanoparticle-based nanocarriers in mice,” *International Journal of Nanomedicine*, vol. 15, pp. 8383–8400, 2020.

[240] S. K. Libutti, G. F. Paciotti, A. A. Byrnes et al., “Results of a completed phase i clinical trial of cyt-6091: a pegylated colloidal gold-tfn nanomedicine,” *Journal of Clinical Oncology*, vol. 27, pp. 3586–3586, 2009.

[241] S. K. Libutti, G. F. Paciotti, A. A. Byrnes et al., “Phase i and pharmacokinetic studies of cyt-6091, a novel pegylated colloidal gold-rhtfn nanomedicine,” *Clinical Cancer Research*, vol. 16, pp. 6139–6149, 2010.

[242] G. Batist, K. A. Gelmon, K. N. Chi et al., “Safety, pharmacokinetics, and efficacy of cpxi liposome injection in patients with advanced solid tumors,” *Clinical Cancer Research*, vol. 15, pp. 692–700, 2009.

[243] L. W. Seymour, “Phase ii studies of polymer-doxorubicin (pk1, fcc28068) in the treatment of breast, lung and colorectal cancer,” *International Journal of Oncology*, vol. 34, pp. 1629–1636, 2009.

[244] Y. Matsumura, M. Gotoh, K. Muro et al., “Phase i and pharmacokinetic study of mcc-465, a doxorubicin (dtr) encapsulated in peg immunoliposome, in patients with metastatic stomach cancer,” *Annals of Oncology*, vol. 15, pp. 517–525, 2004.

[245] J. W. Valle, A. Armstrong, C. Newman et al., “A phase 2 study of sp1049c, doxorubicin in p-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction,” *Investigational New Drugs*, vol. 29, pp. 1029–1037, 2011.

[246] E. Galanis, S. K. Carlson, N. R. Foster et al., “Phase i trial of a pathotropic retroviral vector expressing a cytotoxic cyclin g1 construct (rexin-g) in patients with advanced pancreatic cancer,” *Molecular Therapy*, vol. 16, pp. 979–984, 2008.

[247] T. Hamaguchi, K. Kato, H. Yasui et al., “A phase i and pharmacokinetic study of nk105, a paclitaxel-incorporating micellar nanoparticle formulation,” *British Journal of Cancer*, vol. 97, pp. 170–176, 2007.

[248] G. Stathopoulos, T. Boulikas, M. Vougiouka, S. Rigatos, and J. Stathopoulos, “Liposomal cisplatin combined with gemcitabine in pretreated advanced pancreatic cancer patients: a phase i-ii study,” *Oncology Reports*, vol. 15, 2006.

[249] W. Kim, K. Y. Na, K. H. Lee, H. W. Lee, J. K. Lee, and K. T. Kim, “Selective uptake of epidermal growth factor-conjugated gold nanoparticle (egf-gnp) facilitates non-thermal plasma (ntp)-mediated cell death,” *Scientific Reports*, vol. 7, p. 10971, 2017.

[250] S. Irani, Z. Shahmirani, S. M. Atyabi, and S. Mirpoor, “Induction of growth arrest in colorectal cancer cells by cold plasma and gold nanoparticles,” *Archives of Medical Science*, vol. 11, pp. 1286–1295, 2015.

[251] A. Dzimitrowicz, A. Bielawska-Pohl, P. Pohl et al., “Application of oil-in-water nanoemulsion carrying size-defined gold nanoparticles synthesized by non-thermal plasma for the human breast cancer cell lines migration and apoptosis,” *Plasma Chemistry and Plasma Processing*, vol. 40, pp. 1037–1062, 2020.

[252] P. Jawaid, M. U. Rehman, Q. L. Zhao et al., “Helium-based cold atmospheric plasma-induced reactive oxygen species-mediated apoptotic pathway attenuated by platinum nanoparticles,” *Journal of Cellular and Molecular Medicine*, vol. 20, pp. 1737–1748, 2016.

[253] G. Kim, S. R. Park, G. C. Kim, and J. K. Lee, “Targeted cancer treatment using anti-egfr and -tfr antibody-conjugated gold nanoparticles stimulated by nonthermal air plasma,” *Plasma Medicine*, vol. 1, pp. 45–54, 2011.

[254] D. Sun, J. McLaughlan, L. Zhang et al., “Atmospheric pressure plasma-synthesized gold nanoparticle/carbon nanotube hybrids for photothermal conversion,” *Langmuir*, vol. 35, pp. 4577–4588, 2019.